U.S. patent application number 11/554571 was filed with the patent office on 2007-05-17 for methods of hormonal treatment utilizing ascending-dose extended cycle regimens.
This patent application is currently assigned to Duramed Pharmaceuticals, Inc.. Invention is credited to Lance J. Bronnenkant, Charles E. Diliberti, Kathleen Z. Reape.
Application Number | 20070111975 11/554571 |
Document ID | / |
Family ID | 39864644 |
Filed Date | 2007-05-17 |
United States Patent
Application |
20070111975 |
Kind Code |
A1 |
Diliberti; Charles E. ; et
al. |
May 17, 2007 |
Methods of Hormonal Treatment Utilizing Ascending-Dose Extended
Cycle Regimens
Abstract
The present invention provides ascending-dose extended cycle
regimens in which a female is administered an estrogen and a
progestin for a period of greater than 30 or 31 consecutive days,
optionally followed by a hormone-free period or by a period of
administration of estrogen. The disclosed regimens can be
administered to a female to provide contraceptive and
non-contraceptive benefits.
Inventors: |
Diliberti; Charles E.;
(Montclair, NJ) ; Reape; Kathleen Z.; (Bryn Mawr,
PA) ; Bronnenkant; Lance J.; (Snyder, NY) |
Correspondence
Address: |
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 NEW YORK AVENUE, N.W.
WASHINGTON
DC
20005
US
|
Assignee: |
Duramed Pharmaceuticals,
Inc.
Cincinnati
OH
|
Family ID: |
39864644 |
Appl. No.: |
11/554571 |
Filed: |
October 30, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11245471 |
Oct 7, 2005 |
|
|
|
11554571 |
Oct 30, 2006 |
|
|
|
60684568 |
May 26, 2005 |
|
|
|
60616424 |
Oct 7, 2004 |
|
|
|
Current U.S.
Class: |
514/170 |
Current CPC
Class: |
A61K 31/56 20130101;
A61P 15/18 20180101; A61K 31/57 20130101; A61K 31/567 20130101;
A61P 17/10 20180101; A61P 43/00 20180101; A61K 31/56 20130101; A61K
2300/00 20130101; A61K 31/567 20130101; A61K 2300/00 20130101; A61K
31/57 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
514/170 |
International
Class: |
A61K 31/57 20060101
A61K031/57; A61K 31/56 20060101 A61K031/56 |
Claims
1. A method of contraception, the method comprising: administering
to a female in need thereof an estrogen and a progestin for a
period of greater than 30 consecutive days, wherein the estrogen
and progestin are administered in at least three phases, wherein a
daily dosage of estrogen in a second phase is equal to or higher
than a daily dosage of estrogen in a first phase, wherein a daily
dosage of estrogen in a third phase is equal to or higher than the
daily dosage of estrogen in the second phase, wherein a total daily
dosage of estrogen and progestin in the second phase is higher than
a total daily dosage of estrogen and progestin in the first phase,
and wherein a total daily dosage of estrogen and progestin in the
third phase is higher than the total daily dosage of estrogen and
progestin in the second phase.
2. The method of claim 1, wherein the daily dosages of progestin in
the first, second, and third phases are equal to each other.
3. The method of claim 1, wherein a daily dosage of progestin in
the second phase is higher than a daily dosage of progestin in the
first phase, and a daily dosage of progestin in the third phase is
higher than the daily dosage of progestin in the second phase.
4. The method of claim 1, wherein a daily dosage of progestin in
the second phase is equal to a daily dosage of progestin in the
first phase, and a daily dosage of progestin in the third phase is
higher than the daily dosage of progestin in the second phase.
5. The method of claim 1, wherein a daily dosage of progestin in
the second phase is higher than a daily dosage of progestin in the
first phase, and a daily dosage of progestin in the third phase is
equal to the daily dosage of progestin in the second phase.
6. The method of claim 1, wherein a daily dosage of progestin in
the second phase is less than twice a daily dosage of progestin in
the first phase.
7. The method of claim 1, wherein a daily dosage of progestin in
the third phase is less than twice a daily dosage of progestin in
the second phase.
8. The method of claim 2, wherein each of the daily dosages of
progestin is equivalent to 150 .mu.g of levonorgestrel.
9. The method of claim 1, wherein the daily dosage of progestin in
the first phase is equivalent to 100 .mu.g of levonorgestrel.
10. The method of claim 1, wherein the daily dosage of progestin in
the second phase is equivalent to 125 .mu.g of levonorgestrel.
11. The method of claim 1, wherein the daily dosage of progestin in
the third phase is equivalent to 150 .mu.g of levonorgestrel.
12. The method of claim 1, wherein the daily dosages of estrogen in
the first, second, and third phases are equal to each other.
13. The method of claim 1, wherein the daily dosage of estrogen in
the second phase is higher than the daily dosage of estrogen in the
first phase, and the daily dosage of estrogen in the third phase is
higher than the daily dosage of estrogen in the second phase.
14. The method of claim 1, wherein the daily dosage of estrogen in
the second phase is equal to the daily dosage of estrogen in the
first phase, and the daily dosage of estrogen in the third phase is
higher than the daily dosage of estrogen in the second phase.
15. The method of claim 1, wherein the daily dosage of estrogen in
the second phase is higher than the daily dosage of estrogen in the
first phase, and the daily dosage of estrogen in the third phase is
equal to the daily dosage of estrogen in the second phase.
16. The method of claim 1, wherein the daily dosage of estrogen in
the second phase is less than twice the daily dosage of estrogen in
the first phase.
17. The method of claim 1, wherein the daily dosage of estrogen in
the third phase is less than twice the daily dosage of estrogen in
the second phase.
18. The method of claim 1, wherein the daily dosage of estrogen in
the first phase is equivalent to 15 .mu.g to 25 .mu.g of ethinyl
estradiol.
19. The method of claim 18, wherein the daily dosage of estrogen in
the first phase is equivalent to 20 .mu.g of ethinyl estradiol.
20. The method of claim 1, wherein the daily dosage of estrogen in
the second phase is equivalent to 20 .mu.g to 30 .mu.g of ethinyl
estradiol.
21. The method of claim 20, wherein the daily dosage of estrogen in
the second phase is equivalent to 25 .mu.g of ethinyl
estradiol.
22. The method of claim 1, wherein the daily dosage of estrogen in
the third phase is equivalent to 25 .mu.g to 35 .mu.g of ethinyl
estradiol.
23. The method of claim 22, wherein the daily dosage of estrogen in
the third phase is equivalent to 30 .mu.g of ethinyl estradiol.
24-26. (canceled)
27. The method of claim 1, wherein the estrogen and progestin are
administered for a period of 31 to 190 consecutive days.
28-33. (canceled)
34. The method of claim 27, wherein the estrogen and progestin are
administered for a period of 74 to 96 days.
35. (canceled)
36. The method of claim 34, wherein the estrogen and progestin are
administered for a period of 84 days.
37-39. (canceled)
40. The method of claim 36, wherein the first phase is 21 days, the
second phase is 21 days, and the third phase is 42 days.
41. The method of claim 36, wherein the first phase is 21 days, the
second phase is 42 days, and the third phase is 21 days.
42. The method of claim 36, wherein the first phase is 42 days, the
second phase is 21 days, and the third phase is 21 days.
43-57. (canceled)
58. The method of claim 1, further comprising a hormone-free
period.
59. The method of claim 58, wherein the hormone-free period is 2 to
10 consecutive days.
60. The method of claim 1, further comprising administering
estrogen for a period of 2 to 10 consecutive days.
61. The method of claim 60, comprising administering estrogen for a
period of 7 consecutive days.
62. The method of claim 60, wherein the estrogen that is
administered for the period of 2 to 10 consecutive days is in a
daily dosage equivalent to 5 .mu.g to 50 .mu.g of ethinyl
estradiol.
63. The method of claim 61, wherein the estrogen that is
administered for a period of 7 days is in a daily dosage equivalent
to 10 .mu.g of ethinyl estradiol.
64. The method of claim 1, further comprising administering a
second active agent.
65. The method of claim 64, wherein the second active agent is
administered (i) during a hormone-free period, (ii) in combination
with an estrogen for a period of 2 to 10 consecutive days, (iii)
continuously, (iv) intermittently, (v) one time, or (vi) once
weekly.
66. The method of claim 64, wherein the second active agent is
selected from the group consisting of calcium, iron, and folic
acid.
67. The method of claim 1, further comprising administering an
antidepressant.
68. The method of claim 67, wherein the antidepressant is
administered (i) during a hormone-free period, (ii) in combination
with an estrogen for a period of 2 to 10 consecutive days, (iii)
continuously, (iv) intermittently, (v) one time, or (vi) once
weekly.
69-70. (canceled)
71. The method of claim 1, further comprising monophasically
administering an estrogen and a progestin.
72. The method of claim 71, wherein the estrogen and the progestin
are monophasically administered for a period of greater than 30
consecutive days.
73-76. (canceled)
77. A method of contraception, the method comprising: administering
to a female in need thereof an estrogen and a progestin for a
period of greater than 42 consecutive days, wherein the estrogen
and progestin are administered in at least two phases, wherein a
total daily dosage of estrogen and progestin in a second phase is
higher than a total daily dosage of estrogen and progestin in a
first phase, and wherein a daily dosage of progestin in the second
phase is less than twice a daily dosage of progestin in the first
phase.
78. The method of claim 77, wherein the daily dosages of progestin
in the first and second phases are equal to each other.
79. The method of claim 77, wherein the daily dosage of progestin
in the second phase is higher than the daily dosage of progestin in
the first phase.
80. The method of claim 78, wherein each of the daily dosages of
progestin is equivalent to 150 .mu.g of levonorgestrel.
81. The method of claim 77, wherein the daily dosage of progestin
in the first phase is equivalent to 100 .mu.g of
levonorgestrel.
82. The method of claim 77, wherein the daily dosage of progestin
in the second phase is equivalent to 125 .mu.g of
levonorgestrel.
83. The method of claim 77, wherein the daily dosages of estrogen
in the first and second phases are equal to each other.
84. The method of claim 77, wherein a daily dosage of estrogen in
the second phase is higher than a daily dosage of estrogen in the
first phase.
85. The method of claim 77, wherein a daily dosage of estrogen in
the second phase is less than twice a daily dosage of estrogen in
the first place.
86. The method of claim 77, wherein a daily dosage of estrogen in
the first phase is equivalent to 15 .mu.g to 25 .mu.g of ethinyl
estradiol.
87. The method of claim 77, wherein a daily dosage of estrogen in
the second phase is equivalent to 20 .mu.g to 30 .mu.g of ethinyl
estradiol.
88-102. (canceled)
103. The method of claim 77, further comprising a hormone-free
period.
104. The method of claim 103, wherein the hormone-free period is 2
to 10 consecutive days.
105. The method of claim 77, further comprising administering
estrogen for a period of 2 to 10 consecutive days.
106. The method of claim 105, wherein the estrogen that is
administered for the period of 2 to 10 consecutive days is in a
daily dosage that is equivalent to 5 .mu.g to 50 .mu.g of ethinyl
estradiol.
107. The method of claim 77, further comprising administering a
second active agent.
108. The method of claim 107, wherein the second active agent is
administered (i) during a hormone-free period, (ii) in combination
with an estrogen for a period of 2 to 10 consecutive days, (iii)
continuously, (iv) intermittently, (v) one time, or (vi) once
weekly.
109. The method of claim 107, wherein the second active agent is
selected from the group consisting of calcium, iron, and folic
acid.
110. The method of claim 77, further comprising administering an
antidepressant.
111. The method of claim 110, wherein the antidepressant is
administered (i) during a hormone-free period, (ii) in combination
with an estrogen for a period of 2 to 10 consecutive days, (iii)
continuously, (iv) intermittently, (v) one time, or (vi) once
weekly.
112-113. (canceled)
114. The method of claim 77, further comprising monophasically
administering an estrogen and a progestin.
115. The method of claim 114, wherein the estrogen and the
progestin are monophasically administered for a period of greater
than 30 consecutive days.
116-119. (canceled)
120. A pharmaceutical kit comprising: a first vaginal ring capable
of providing a daily dosage of estrogen and a daily dosage of
progestin; a second vaginal ring capable of providing a daily
dosage of estrogen that is equal to or higher than that of the
first vaginal ring and capable of providing a total daily dosage of
estrogen and progestin that is higher than that of the first
vaginal ring; and a third vaginal ring capable of providing a daily
dosage of estrogen that is equal to or higher than that of the
second vaginal ring and capable of providing a total daily dosage
of estrogen and progestin that is higher than that of the second
vaginal ring; wherein the vaginal rings are capable of providing
estrogen and progestin for a period of greater than 30 consecutive
days.
121. A pharmaceutical kit comprising: a first vaginal ring capable
of providing a daily dosage of estrogen and a daily dosage of
progestin; a second vaginal ring capable of providing a total daily
dosage of estrogen and progestin that is higher than that of the
first vaginal ring and capable of providing a daily dosage of
progestin that is less than twice that of the first vaginal ring;
wherein the vaginal rings are capable of providing estrogen and
progestin for a period of greater than 30 consecutive days.
122. The pharmaceutical kit of claim 121, wherein the second
vaginal ring is capable of providing a daily dosage of estrogen
that is equal to or higher than that of the first vaginal ring.
123. A pharmaceutical kit comprising: a first transdermal device
capable of providing a daily dosage of estrogen and a daily dosage
of progestin; a second transdermal device capable of providing a
daily dosage of estrogen that is equal to or higher than that of
the first transdermal device and capable of providing a total daily
dosage of estrogen and progestin that is higher than that of the
first transdermal device; and a third transdermal device capable of
providing a daily dosage of estrogen that is equal to or higher
than that of the second transdermal device and capable of providing
a total daily dosage of estrogen and progestin that is higher than
that of the second transdermal device; wherein the transdermal
devices are capable of providing estrogen and progestin for a
period of greater than 30 consecutive days.
124. A pharmaceutical kit comprising: a first transdermal device
capable of providing a daily dosage of estrogen and a daily dosage
of progestin; a second transdermal device capable of providing a
total daily dosage of estrogen and progestin that is higher than
that of the first transdermal device and capable of providing a
daily dosage of progestin that is less than twice that of the first
transdermal device; wherein the transdermal devices are capable of
providing estrogen and progestin for a period of greater than 30
consecutive days.
125. The pharmaceutical kit of claim 124, wherein the second
transdermal device is capable of providing a daily dosage of
estrogen that is equal to or higher than that of the first
transdermal device.
126. A pharmaceutical kit comprising: a first oral dosage capable
of providing a daily dosage of estrogen and a daily dosage of
progestin; a second oral dosage capable of providing a daily dosage
of estrogen that is equal to or higher than that of the first oral
dosage and capable of providing a total daily dosage of estrogen
and progestin that is higher than that of the first oral dosage;
and a third oral dosage capable of providing a daily dosage of
estrogen that is equal to or higher than that of the second oral
dosage and capable of providing a total daily dosage of estrogen
and progestin that is higher than that of the second oral dosage;
wherein the oral dosages are capable of providing estrogen and
progestin for a period of greater than 30 consecutive days.
127. A pharmaceutical kit comprising: a first oral dosage capable
of providing a daily dosage of estrogen and a daily dosage of
progestin; a second oral dosage capable of providing a total daily
dosage of estrogen and progestin that is higher than that of the
first oral dosage and capable of providing a daily dosage of
progestin that is less than twice that of the first oral dosage;
wherein the oral dosages are capable of providing estrogen and
progestin for a period of greater than 42 consecutive days.
128. The pharmaceutical kit of claim 127, wherein the second oral
dosage is capable of providing a daily dosage of estrogen that is
equal to or higher than that of the first oral dosage.
129. The pharmaceutical kit of claim 126, comprising 21 first oral
dosages, 21 second oral dosages, and 42 third oral dosages.
130. The pharmaceutical kit of claim 126, comprising 21 first oral
dosages, 42 second oral dosages, and 21 third oral dosages.
131. The pharmaceutical kit of claim 126, comprising 42 first oral
dosages, 21 second oral dosages, and 21 third oral dosages.
132. The pharmaceutical kit of claim 126, wherein the first oral
dosage is capable of providing 20 .mu.g of ethinyl estradiol and
150 .mu.g of levonorgestrel, the second oral dosage is capable of
providing 25 .mu.g of ethinyl estradiol and 150 .mu.g of
levonorgestrel, and the third oral dosage is capable of providing
30 .mu.g of ethinyl estradiol and 150 .mu.g of levonorgestrel.
133. The pharmaceutical kit of claim 126, further comprising a
fourth oral dosage capable of providing estrogen.
134. The pharmaceutical kit of claim 133, wherein the fourth oral
dosage comprises a daily equivalent of 10 .mu.g of ethinyl
estradiol.
135. The pharmaceutical kit of claim 133, comprising 7 fourth oral
dosages.
136. A method of treating acne, the method comprising:
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 30 consecutive days, wherein
the estrogen and progestin are administered in at least three
phases, wherein a daily dosage of estrogen in a second phase is
equal to or higher than a daily dosage of estrogen in a first
phase, wherein a daily dosage of estrogen in a third phase is equal
to or higher than the daily dosage of estrogen in the second phase,
wherein a total daily dosage of estrogen and progestin in the
second phase is higher than a total daily dosage of estrogen and
progestin in the first phase, and wherein a total daily dosage of
estrogen and progestin in the third phase is higher than the total
daily dosage of estrogen and progestin in the second phase.
137. A method of treating acne, the method comprising:
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 42 consecutive days, wherein
the estrogen and progestin are administered in at least two phases,
wherein a total daily dosage of estrogen and progestin in a second
phase is higher than a total daily dosage of estrogen and progestin
in a first phase, and wherein a daily dosage of progestin in the
second phase is less than twice a daily dosage of progestin in the
first phase.
138. A method of treating headache, the method comprising:
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 30 consecutive days, wherein
the estrogen and progestin are administered in at least three
phases, wherein a daily dosage of estrogen in a second phase is
equal to or higher than a daily dosage of estrogen in a first
phase, wherein a daily dosage of estrogen in a third phase is equal
to or higher than the daily dosage of estrogen in the second phase,
wherein a total daily dosage of estrogen and progestin in the
second phase is higher than a total daily dosage of estrogen and
progestin in the first phase, and wherein a total daily dosage of
estrogen and progestin in the third phase is higher than the total
daily dosage of estrogen and progestin in the second phase.
139. A method of treating headache, the method comprising:
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 42 consecutive days, wherein
the estrogen and progestin are administered in at least two phases,
wherein a total daily dosage of estrogen and progestin in a second
phase is higher than a total daily dosage of estrogen and progestin
in a first phase, and wherein a daily dosage of progestin in the
second phase is less than twice a daily dosage of progestin in the
first phase.
140. A method of treating pelvic pain, the method comprising:
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 30 consecutive days, wherein
the estrogen and progestin are administered in at least three
phases, wherein a daily dosage of estrogen in a second phase is
equal to or higher than a daily dosage of estrogen in a first
phase, wherein a daily dosage of estrogen in a third phase is equal
to or higher than the daily dosage of estrogen in the second phase,
wherein a total daily dosage of estrogen and progestin in the
second phase is higher than a total daily dosage of estrogen and
progestin in the first phase, and wherein a total daily dosage of
estrogen and progestin in the third phase is higher than the total
daily dosage of estrogen and progestin in the second phase.
141. A method of treating pelvic pain, the method comprising:
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 42 consecutive days, wherein
the estrogen and progestin are administered in at least two phases,
wherein a total daily dosage of estrogen and progestin in a second
phase is higher than a total daily dosage of estrogen and progestin
in a first phase, and wherein a daily dosage of progestin in the
second phase is less than twice a daily dosage of progestin in the
first phase.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation in part of U.S.
application Ser. No. 11/245,471, filed Oct. 7, 2005, which claims
the benefit of U.S. Provisional Application No. 60/616,424, filed
Oct. 7, 2004, and U.S. Provisional Application No. 60/684,568,
filed May 26, 2005, the contents of which are hereby incorporated
by reference in their entireties.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates to methods of hormonal
treatment by ascending-dose extended administration of an estrogen
and a progestin.
[0004] 2. Related Art
[0005] The human menstrual cycle involves a repetitive sequence of
hormonal changes that result in episodic uterine bleeding.
Normally, each menstrual cycle has a mean interval of 21 to 35
days, conventionally beginning with the first day of menstrual flow
and ending on the day before the next onset of bleeding. Duration
of the menstrual flow is usually 2 to 6 days with loss of about 20
to about 60 ml of blood.
[0006] The menstrual cycle is divided into follicular and luteal
phases, each corresponding to changes occurring in the ovary. These
phases may also be described as proliferative or secretory,
corresponding to changes observed in the uterine endometrium.
Variations in the length of the cycle are usually due to
alterations in the follicular phase, because the luteal phase
length remains relatively constant at 12 to 16 days.
[0007] During the follicular phase, several primary follicles are
recruited for further growth and development. Granulosa cells in
primary follicles possess follicle stimulating hormone (FSH) and
estradiol receptors. Upon FSH stimulation, granulosa cells produce
aromatase. This enzyme converts the androgens androstenedione and
testosterone, made in response to luteinizing hormone (LH) by
thecal cells, to estrone and estradiol, respectively. Granulosa
cells respond to estradiol by undergoing mitosis to increase the
number of granulosa cells and estradiol production. By day 7 of the
cycle, one enlarging primary follicle is selected by unknown
processes to be the follicle that will release the oocyte at
ovulation.
[0008] The midcycle rise in plasma estradiol stimulates the large
midcycle LH surge. This midcycle LH surge triggers resumption of
meiosis within the oocyte and luteinization of the granulosa cells
within the preovulatory follicle. Immediately before ovulation, the
outer follicular wall begins to dissolve and an oocyte is released
approximately 24 to 36 hours from the onset of the LH surge.
[0009] After ovulation, granulosa cells and the surrounding theca
cells enlarge, accumulate lipid, and become transformed into lutein
cells. This begins the luteal phase of the menstrual cycle. These
cells form a new vascularized structure called the corpus luteum,
which secretes estradiol and progesterone. LH maintains the corpus
luteum during the luteal phase and, acting via the adenyl cyclase
system, stimulates progesterone production. If pregnancy does not
occur, lutein cells degenerate, and diminished hormone secretion
precedes menstruation. Menstruation is immediately followed by the
onset of another menstrual cycle.
[0010] Because endometrial proliferation serves to prepare the
uterus for an impending pregnancy, manipulation of hormones and of
the uterine environment can provide contraception. For example,
estrogens are known to decrease FSH secretion by feedback
inhibition. Under certain circumstances, estrogens can also inhibit
LH secretion, once again by negative feedback. Under normal
circumstances, the spike of circulating estrogen found just prior
to ovulation induces the surge of gonadotropic hormones that occurs
just prior to and results in ovulation. High doses of estrogen
immediately post-coitally also can prevent conception probably due
to interference with implantation.
[0011] Progestins can also provide contraception. Endogenous
progesterone after estrogen is responsible for the progestational
changes of the endometrium and the cyclic changes of cells and
tissue in the cervix and the vagina. Administration of progestin
makes the cervical mucus thick, tenacious and cellular which is
believed to impede spermatozoal transport. Administration of
progestin also inhibits luteinizing hormone secretion and blocks
ovulation in humans.
[0012] The most prevalent form of oral contraception is a pill that
combines both an estrogen and a progestin, a so-called combined
oral contraceptive preparation. Alternatively, there are
contraceptive preparations that comprise progestin only. However,
the progestin-only preparations have a more varied spectrum of side
effects than do the combined preparations, especially more
breakthrough bleeding. As a result, the combined preparations are
the preferred oral contraceptives in use today (Sheth et al.,
Contraception 25:243 (1982)).
[0013] Whereas the conventional 21 day pill packs with a 7 day
placebo interval worked well when oral contraceptives were of
higher dosage, as the doses have come down, for both the estrogen
and progestin components, bleeding problems have increased in
frequency, especially in the early months of oral contraceptive
use, but even persistently so in some patients.
[0014] There exists a need for contraceptives that reduce bleeding
problems and/or have additional benefits for women.
BRIEF SUMMARY OF THE INVENTION
[0015] The present invention provides ascending-dose extended cycle
regimens in which a female is administered an estrogen and a
progestin for a period of greater than 30 or 31 consecutive days,
optionally followed by a hormone-free period of 2 to 10 consecutive
days or by administration of estrogen for a period of 2 to 10
consecutive days.
[0016] The present invention is directed to a method of
contraception, the method comprising administering to a female in
need thereof an estrogen and a progestin for a period of greater
than 30 or 31 consecutive days, wherein the estrogen and progestin
are administered in at least three phases, wherein a daily dosage
of estrogen in a second phase is equal to or higher than a daily
dosage of estrogen in a first phase, wherein a daily dosage of
estrogen in a third phase is equal to or higher than the daily
dosage of estrogen in the second phase, wherein a total daily
dosage of estrogen and progestin in the second phase is higher than
a total daily dosage of estrogen and progestin in the first phase,
and wherein a total daily dosage of estrogen and progestin in the
third phase is higher than the total daily dosage of estrogen and
progestin in the second phase.
[0017] The present invention is also directed to a method of
contraception, the method comprising administering to a female in
need thereof an estrogen and a progestin for a period of greater
than 30, 31, or 42 consecutive days, wherein the estrogen and
progestin are administered in at least two phases, wherein a total
daily dosage of estrogen and progestin in a second phase is higher
than a total daily dosage of estrogen and progestin in a first
phase, and wherein a daily dosage of progestin in the second phase
is less than twice a daily dosage of progestin in the first
phase.
[0018] The ascending-dose extended cycle regimens provide a number
of non-contraceptive benefits, as well as contraceptive benefits.
For example, the present invention is also directed to a method of
reducing breakthrough bleeding in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein.
DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention is directed to ascending-dose extended
cycle regimens that are useful in the treatment of a variety of
conditions and disorders occurring in females of child-bearing age,
in peri-menopausal females, and/or in menopausal females. In
accordance with the present invention, a female is administered an
ascending-dose extended cycle regimen of an estrogen and a
progestin (or progestogen) for a period of greater than 30 or 31
consecutive days.
[0020] An "ascending-dose extended cycle regimen" of the present
invention refers to a regimen disclosed herein in which an estrogen
and a progestin are administered for a period of greater than 30 or
31 consecutive days, wherein the estrogen and progestin are
administered in at least three phases, wherein a daily dosage of
estrogen in a second phase is equal to or higher than a daily
dosage of estrogen in a first phase, wherein a daily dosage of
estrogen in a third phase is equal to or higher than the daily
dosage of estrogen in the second phase, wherein a total daily
dosage of estrogen and progestin in the second phase is higher than
a total daily dosage of estrogen and progestin in the first phase,
and wherein a total daily dosage of estrogen and progestin in the
third phase is higher than the total daily dosage of estrogen and
progestin in the second phase.
[0021] An "ascending-dose extended cycle regimen" of the present
invention also refers to a regimen disclosed herein in which an
estrogen and a progestin are administered for a period of greater
than 30, 31, or 42 consecutive days, wherein the estrogen and
progestin are administered in at least two phases, wherein a total
daily dosage of estrogen and progestin in a second phase is higher
than a total daily dosage of estrogen and progestin in a first
phase, and wherein a daily dosage of progestin in the second phase
is less than twice a daily dosage of progestin in the first
phase.
[0022] As used herein, "extended cycle regimen" refers to a regimen
in which a contraceptive composition is administered for a period
of greater than 30 or 31 days.
[0023] As used herein, "female" refers to any animal classified as
a mammal, including humans and non-humans, such as, but not limited
to, domestic and farm animals, zoo animals, sports animals, and
pets.
[0024] "Peri-menopausal female" refers to a woman who has not yet
definitely arrived at menopause but who is experiencing symptoms
associated with menopause. "Peri-menopause" means "about or around
the time of menopause." It encompasses the years preceding the last
menstrual period during which ovarian function declines and
ultimately ceases and can include the presence of symptoms and
irregular cycles. "Menopausal female" refers to a woman who has
definitely arrived at menopause and may be experiencing symptoms
associated with menopause. Menopause or post-menopause is the
permanent cessation of menstruation after the loss of ovarian
activity and is generally defined clinically as the absence of
menstruation for about one year. Menopause may occur naturally in a
woman or it may be artificially induced, e.g., through surgical or
chemical means. For example, removal of the ovaries, which can
occur, e.g., through hysterectomy, frequently leads to symptoms
associated with menopause.
[0025] The terms "treat" and "treatment" refer to both therapeutic
treatment and prophylactic or preventative measures, wherein the
object is to prevent or slow down (lessen) an undesired
physiological condition, disorder or disease, or obtain beneficial
or desired clinical results. For purposes of this invention,
beneficial or desired clinical results include, but are not limited
to, alleviation of symptoms; diminishment of extent of condition,
disorder or disease; stabilized (i.e., not worsening) state of
condition, disorder or disease; delay in onset or slowing of
condition, disorder or disease progression; amelioration of the
condition, disorder or disease state, remission (whether partial or
total), whether detectable or undetectable; or enhancement or
improvement of condition, disorder or disease. Treatment includes
eliciting a clinically significant response, without excessive
levels of side effects. Treatment also includes prolonging survival
as compared to expected survival if not receiving treatment.
[0026] The term "continuous" or "consecutive" in reference to
"administration" means that the frequency of administration is at
least once daily. Note, however, that the frequency of
administration can be greater than once daily and still be
"continuous," e.g., twice or even three times daily, as long as the
dosage levels as specified herein are not exceeded.
[0027] The term "daily dosage," "daily dosage level," "daily dosage
amount," or "daily dose" means the total amount of estrogen (and/or
progestin) administered per day. Thus, for example, "continuous
administration" of a progestin to a woman at a "daily dosage level"
of 30 .mu.g means that the woman receives a total of 30 .mu.g of
progestin on a daily basis, whether the progestin is administered
as a single 30 .mu.g dose or, e.g., three separate 10 .mu.g doses.
A conventional means of continuously administering an estrogen or
progestin is as a single daily oral dose at the prescribed daily
dosage level.
[0028] As used herein, "about" refers to plus or minus 10% of the
indicated number. For example, "about 10 .mu.g" indicates a range
of 9 .mu.g to 11 .mu.g.
Dosages and Regimens
[0029] The present invention is directed to a method of providing
an ascending-dose extended cycle regimen, the method comprising
administering to a female in need thereof an estrogen and a
progestin for a period of greater than 30 or 31 consecutive days,
wherein the estrogen and progestin are administered in at least
three phases, wherein a daily dosage of estrogen in a second phase
is equal to or higher than a daily dosage of estrogen in a first
phase, wherein a daily dosage of estrogen in a third phase is equal
to or higher than the daily dosage of estrogen in the second phase,
wherein a total daily dosage of estrogen and progestin in the
second phase is higher than a total daily dosage of estrogen and
progestin in the first phase, and wherein a total daily dosage of
estrogen and progestin in the third phase is higher than the total
daily dosage of estrogen and progestin in the second phase.
[0030] The present invention is also directed to a method of
providing an ascending-dose extended cycle regimen, the method
comprising administering to a female in need thereof an estrogen
and a progestin for a period of greater than 30, 31, or 42
consecutive days, wherein the estrogen and progestin are
administered in at least two phases, wherein a total daily dosage
of estrogen and progestin in a second phase is higher than a total
daily dosage of estrogen and progestin in a first phase, and
wherein a daily dosage of progestin in the second phase is less
than twice a daily dosage of progestin in the first phase.
[0031] In some aspects of the invention, the daily dosage of
progestin in the first and second phases are equal to each other.
In further aspects of the invention, the daily dosages of progestin
in the first, second, and third phases are equal to each other. The
daily dosage of progestin can be, but is not limited to, the
equivalent of 150 .mu.g of levonorgestrel for the first, second,
and third phases.
[0032] In some aspects of the invention, the daily dosage of
progestin in the second phase is higher than the daily dosage of
progestin in the first phase. In further aspects of the invention,
the daily dosage of progestin in the third phase is higher than the
daily dosage of progestin in the second phase.
[0033] In some aspects of the invention, the daily dosage of
progestin in the second phase is equal to the daily dosage of
progestin in the first phase and the daily dosage of progestin in
the third phase is higher than the daily dosage of progestin in the
second phase. In other aspects of the invention, the daily dosage
of progestin in the second phase is higher than the daily dosage of
progestin in the first phase and the daily dosage of progestin in
the third phase is equal to the daily dosage of progestin in the
second phase.
[0034] In some aspects of the invention, the daily dosage of
progestin in the second phase is less than twice the daily dosage
of progestin in the first phase. In further aspects of the
invention, the daily dosage of progestin in the third phase is less
than twice the daily dosage of progestin in the second phase.
[0035] The daily dosage of progestin in the first phase can be, but
is not limited to, the equivalent of 95 .mu.g to 105 .mu.g, 97
.mu.g to 102 .mu.g, or 99 .mu.g to 101 .mu.g of levonorgestrel. For
example, the daily dosage of progestin in the first phase can be
the equivalent of 100 .mu.g levonorgestrel. The daily dosage of
progestin in the second phase can be, but is not limited to, the
equivalent of 120 .mu.g to 130 .mu.g, 122 .mu.g to 128 .mu.g, or
124 .mu.g to 126 .mu.g of levonorgestrel. For example, the daily
dosage of progestin in the second phase can be the equivalent of
125 .mu.g of levonorgestrel. The daily dosage of progestin in the
third phase can be, but is not limited to, the equivalent of 145
.mu.g to 155 .mu.g, 147 .mu.g to 153 .mu.g, or 149 .mu.g to 151
.mu.g of levonorgestrel. For example, the daily dosage of progestin
in the third phase can be the equivalent of 150 .mu.g of
levonorgestrel.
[0036] In some aspects of the invention, the progestin used is
trimegestone. The total daily dosage of trimegestone can be, but is
not limited to, 0.25 mg to 2.0 mg, 0.5 mg to 1.5 mg, 0.75 mg to
1.25 mg, or 1.0 mg. In those aspects of the invention in which
trimegestone is administered transdermally or vaginally, the total
daily dosage of trimegestone can be, but is not limited to, 0.175
mg to 2.0 mg, 0.35 mg to 1.5 mg, 0.52 mg to 1.25 mg, or 0.7 mg to
1.0 mg.
[0037] In further aspects of the invention, the daily dosage of
trimegestone in the first and second phases of an ascending-dose
extended cycle regimen can be 1.0 mg. In still further embodiments,
the daily dosage of trimegestone in the first, second, and third
phases of an ascending-dose extended cycle regimen can be 1.0 mg.
In those aspects of the invention in which trimegestone is
administered transdermally or vaginally, the daily dosage of
trimegestone in the first and second phases of an ascending-dose
extended cycle regimen can be 0.7 mg to 1.0 mg. In yet other
embodiments, the daily dosage of transdermally- or
vaginally-administered trimegestone in the first, second, and third
phases of an ascending-dose extended cycle regimen can be 0.7 mg to
1.0 mg.
[0038] The daily dosage of trimegestone in the first phase can be,
but is not limited to, 0.25 mg to 1.25 mg, 0.5 mg to 1.0 mg, or
0.75 mg. The daily dosage of trimegestone in the second phase can
be, but is not limited to, 0.5 mg to 1.5 mg, 0.75 mg to 1.25 mg, or
1.0 mg. The daily dosage of trimegestone in the third phase can be,
but is not limited to, 0.75 mg to 1.75 mg, 1.0 mg to 1.5 mg, or
1.25 mg.
[0039] For those aspects of the invention in which the trimegestone
is administered transdermally or vaginally, the daily dosage of
trimegestone in the first phase can be, but is not limited to,
0.175 mg to 1.25 mg, 0.35 mg to 1.0 mg, or 0.52 mg to 0.75 mg. The
daily dosage of transdermally- or vaginally-administered
trimegestone in the second phase can be, but is not limited to,
0.35 mg to 1.5 mg, 0.52 mg to 1.25 mg, or 0.7 mg to 1.0 mg, and the
daily dosage in the third phase can be, but is not limited to, 0.52
mg to 1.75 mg, 0.7 mg to 1.5 mg, or 0.87 mg to 1.25 mg.
[0040] The trimegestone can be administered together with an
estrogen in the ascending-dose extended cycle regimens of the
present invention. In addition, the trimegestone can be
administered in combination with an estrogen in other oral
contraceptive regimens.
[0041] For example, the daily dosage of trimegestone for an
estrogen and progestin combined 28-day oral contraceptive can be,
but is not limited to, 0.25 mg to 2.0 mg, 0.5 mg to 1.75 mg, 0.75
mg to 1.25 mg, or 1.0 mg.
[0042] In some aspects of the invention, the daily dosage of
estrogen in each of the first and second phases are equal to each
other. In further aspects of the invention, the daily dosage of
estrogen in each of the first, second, and third phases are equal
to each other.
[0043] In some aspects of the invention, the daily dosage of
estrogen in the second phase is higher than the daily dosage of
estrogen in the first phase. In further aspects of the invention,
the daily dosage of estrogen in the third phase is higher than the
daily dosage of estrogen in the second phase.
[0044] In some aspects of the invention, the daily dosage of
estrogen in the second phase is equal to the daily dosage of
estrogen in the first phase and the daily dosage of estrogen in the
third phase is higher than the daily dosage of estrogen in the
second phase. In other aspects of the invention, the daily dosage
of estrogen in the second phase is higher than the daily dosage of
estrogen in the first phase and the daily dosage of estrogen in the
third phase is equal to the daily dosage of estrogen in the second
phase.
[0045] In some aspects of the invention, the daily dosage of
estrogen in the second phase is less than twice the daily dosage of
estrogen in the first phase. In further aspects of the invention,
the daily dosage of estrogen in the third phase is less than twice
the daily dosage of estrogen in the second phase.
[0046] In some aspects of the invention, the daily dosage of
estrogen in the first phase is the equivalent of 15 .mu.g to 25
.mu.g, 17 .mu.g to 23 .mu.g, or 19 .mu.g to 21 .mu.g of ethinyl
estradiol. For example, the daily dosage of estrogen in the first
phase can be the equivalent of 20 .mu.g of ethinyl estradiol.
[0047] In some aspects of the invention, the daily dosage of
estrogen in the second phase is the equivalent of 20 .mu.g to 30
.mu.g, 22 .mu.g to 28 .mu.g, or 24 .mu.g to 26 .mu.g of ethinyl
estradiol. For example, the daily dosage of estrogen in the second
phase can be the equivalent of 25 .mu.g of ethinyl estradiol.
[0048] In some aspects of the invention, the daily dosage of
estrogen in the third phase is the equivalent of 25 .mu.g to 35
.mu.g, 27 .mu.g to 33 .mu.g, or 29 .mu.g to 31 .mu.g of ethinyl
estradiol. For example, the daily dosage of estrogen in the third
phase can be the equivalent of 30 .mu.g of ethinyl estradiol.
[0049] In some aspects of the invention, the estrogen and progestin
are administered orally and the daily dosage of estrogen is the
equivalent of 15 .mu.g to 50 .mu.g of ethinyl estradiol and the
daily dosage of progestin is the equivalent of 100 .mu.g to 150
.mu.g of levonorgestrel.
[0050] In some aspects of the invention, the estrogen and progestin
of the ascending-dose extended cycle regimens can be ethinyl
estradiol and levonorgestrel, although other suitable estrogens and
progestins can be employed. If a different estrogen or progestin is
employed, an adjustment in the amount based on the relative potency
or activity can be made. Correlations in potency among the various
estrogens and among the various progestins are known. See, for
example, EP 0 253 607, which is incorporated herein in its entirety
by reference. For example, 30 .mu.g of ethinyl estradiol is about
the equivalent of 60 .mu.g of mestranol or 2,000 .mu.g of
17.beta.-estradiol. Similarly, 0.050 mg of levonorgestrel is about
the equivalent of 0.175 mg of norethindrone acetate, 0.050 mg of
desogestrel, 0.050 mg 3-ketodesogestrel, 0.035 mg of gestodene,
0.100 mg of norgestrel, or 0.35-0.50 mg of trimegestone. It should
be understood that when norgestrel is used in place of
levonorgestrel, its concentration is twice that of levonorgestrel.
Norgestrel (dl-norgestrel) is a racemic mixture of optically active
isomers, while levonorgestrel is one of the optically active
isomers present in norgestrel.
[0051] Equivalent concentrations of estrogens and of progestins can
be determined using either in vitro or in vivo assay methods. See,
for example, Kuhl, H., Drugs 51(2):188-215 (1996); Philibert, D.,
et al, Gynecol. Endocrinol 13:316-326 (1999); and Lundeen, S., et
al., J. Steroid Biochem. Molec. Biol. 78:137-143 (2001), in which
the relative potencies of various progestins are compared using
both in vitro and in vivo test assays. See also, for example,
Dickey, R. P., "Contraceptive Therapy," OBG Management Supplement
(October 2000), pp. 2-6. Each of these documents is incorporated
herein by reference in its entirety.
[0052] For example, various combinations of progestin and estrogen
that have been used in oral contraceptives are shown in Table 1.
TABLE-US-00001 TABLE 1 Combinations of Progestin and Estrogen EE
Norethindrone Equivalent Dose Equivalent Dose Dose Progestin (mg)
Dose (mg) Estrogen (mg) (mg) P/E Ratio Norethynodrel 9.85 9.85
Mestranol 0.150 0.105 93.810 5.00 5.00 0.075 0.053 95.238 2.50 2.50
0.036 0.025 99.206 2.50 2.50 0.100 0.070 35.714 Norethindrone 10.00
10.00 Mestranol 0.060 0.042 238.095 2.00 2.00 0.100 0.070 28.571
1.00 1.00 0.050 0.035 28.571 1.00 1.00 0.080 0.056 17.857
Norethindrone 1.00 1.00 Ethinyl 0.050 0.050 20.000 1.00 1.00
estradiol 0.035 0.035 28.571 (EE) 0.50 0.50 0.035 0.035 14.286 0.40
0.40 0.035 0.035 11.429 Norethindrone 2.50 2.50 EE 0.050 0.050
50.000 acetate 1.00 1.00 0.050 0.050 20.000 0.60 0.60 0.030 0.030
20.000 1.50 1.50 0.030 0.030 50.000 1.00 1.00 0.020 0.020 50.000
Ethynodiol 1.00 1.00 Mestranol 0.100 0.070 14.286 diacetate
Ethynodiol 1.00 1.00 EE 0.050 0.050 20.000 diacetate 1.00 1.00
0.035 0.035 28.571 di-Norgestrel 0.50 0.75 EE 0.050 0.050 10.000
0.30 0.45 0.030 0.030 10.000 Levonorgestrel 0.10 0.35 EE 0.020
0.020 5.000 0.15 0.52 0.030 0.030 5.000 Equivalencies 50 mg
Mestranol = approx. 35 mg Ethinyl estradiol (EE) 0.1 mg
dl-Norgestrel = approx. 0.15 mg Norethindrone
[0053] Each block in Table 1 describes a specific combination of
progestin and estrogen, e.g., norethynodrel and mestranol, and
within each block older combinations are listed first, with
successively newer combinations following.
[0054] Suitable progestins for use in the present invention
include, but are not limited to, natural and synthetic compounds
having progestational activity, such as, for example, progesterone,
levonorgestrel, norethindrone, norethindrone acetate, desogestrel,
gestodene, dienogest, norgestimate, cyproterone acetate,
norelgestromin, etonogestrel, ethynodiol diacetate, norgestrel,
trimegestone, medroxyprogesterone acetate, chlormadinone acetate,
drospirenone, and other natural and/or synthetic gestagens. Esters,
conjugates, and prodrugs of suitable progestins can also be
used.
[0055] The expression "prodrug" denotes a derivative of a known
direct acting drug, which derivative has enhanced delivery
characteristics and therapeutic value as compared to the drug and
is transformed into the active drug by an enzymatic or chemical
process. Ethynodiol diacetate, which is converted in vivo to
norethindrone, is an example of a progestin prodrug that can be
used in the present invention. Additional examples of progestin
prodrugs include, but are not limited to, norgestimate (which is
converted in vivo to 17-deacetyl norgestimate, also known as
norelgestromin), desogestrel (which is converted in vivo to 3-keto
desogestrel, also known as etonogestrel), and norethindrone acetate
(which is converted in vivo to norethindrone).
[0056] Suitable estrogens in the present invention include, but are
not limited to, natural and synthetic compounds having estrogenic
activity, such as, for example, estradiol (17.beta.-estradiol),
17.alpha.-estradiol, estriol, estrone, and their esters, such as
the acetate, sulfate, valerate or benzoate esters of these
compounds, including, for example, estradiol 17.beta.-cypionate,
estradiol 17-propionate, estradiol 3-benzoate, and piperazine
estrone sulfate; ethinyl estradiol; conjugated estrogens (natural
and synthetic); mestranol; agonistic anti-estrogens; and selective
estrogen receptor modulators. Esters, conjugates and prodrugs of
suitable estrogens can also be used. Examples of estrogen prodrugs
that can be used in the present invention include, but are not
limited to, estradiol acetate (which is converted in vivo to
17.beta.-estradiol) and mestranol (which is converted in vivo to
ethinyl estradiol).
[0057] In some aspects of the invention, the estrogen and progestin
are administered for a period of 31 to 190 consecutive days. Each
phase can be, but is not limited to, 7 to 84 days.
[0058] In some aspects of the invention, the estrogen and progestin
are administered for a period of 39 to 61 days, of 42 to 60 days,
of 45 to 57 days, or of 48 to 54 days. For example, the estrogen
and progestin can be administered for a period of 49 days to 53
days. In some embodiments, the estrogen and progestin can be
administered for a period of 49 days or 53 days. The first phase
can be, but is not limited to, 7 to 21 days. The second phase can
be, but is not limited to, 14 to 28 days. The third phase can be,
but is not limited to, 7 to 25 days. In some aspects of the
invention, the first phase is 14 days, the second phase is 21 days,
and the third phase is 14 days. In other aspects of the invention,
the first phase is 14 days, the second phase is 21 days, and the
third phase is 18 days.
[0059] In some embodiments, the first phase can be, but is not
limited to, 7 to 21 days. The second phase can be, but is not
limited to, 7 to 21 days. The third phase can be, but is not
limited to, 14 to 32 days. In some aspects of the invention, the
first phase is 14 days, the second phase is 14 days, and the third
phase is 21 days. In other aspects of the invention, the first
phase is 14 days, the second phase is 14 days, and the third phase
is 25 days.
[0060] In some embodiments, the first phase can be, but is not
limited to, 14 to 28 days. The second phase can be, but is not
limited to, 7 to 21 days. The third phase can be, but is not
limited to, 7 to 25 days. In some aspects of the invention, the
first phase is 21 days, the second phase is 14 days, and the third
phase is 14 days. In other aspects of the invention, the first
phase is 21 days, the second phase is 14 days, and the third phase
is 18 days
[0061] In some aspects of the invention, the estrogen and progestin
are administered for a period of 74 to 96 days, of 77 to 95 days,
of 80 to 92 days, or of 83 to 89 days. For example, the estrogen
and progestin can be administered for a period of 84 days to 88
days. In some embodiments, the estrogen and progestin can be
administered for a period of 84 days or 88 days. The first phase
can be, but is not limited to, 14 to 28 days. The second phase can
be, but is not limited to, 14 to 28 days. The third phase can be,
but is not limited to, 35 to 53 days. In some aspects of the
invention, the first phase is 21 days, the second phase is 21 days,
and the third phase is 42 days. In other aspects of the invention,
the first phase is 21 days, the second phase is 21 days, and the
third phase is 46 days.
[0062] In some embodiments, the first phase can be, but is not
limited to, 14 to 28 days. The second phase can be, but is not
limited to, 35 to 49 days. The third phase can be, but is not
limited to, 14 to 32 days. In some aspects of the invention, the
first phase is 21 days, the second phase is 42 days, and the third
phase is 21 days. In other aspects of the invention, the first
phase is 21 days, the second phase is 42 days, and the third phase
is 25 days.
[0063] In some embodiments, the first phase can be, but is not
limited to, 35 to 49 days. The second phase can be, but is not
limited to, 14 to 28 days. The third phase can be, but is not
limited to, 14 to 32 days. In some aspects of the invention, the
first phase is 42 days, the second phase is 21 days, and the third
phase is 21 days. In other aspects of the invention, the first
phase is 42 days, the second phase is 21 days, and the third phase
is 25 days.
[0064] In some aspects of the invention, the estrogen and progestin
are administered for a period of 95 to 117 days, of 98 to 116 days,
of 101 to 113 days, or of 104 to 110 days. For example, the
estrogen and progestin can be administered for a period of 105 days
to 109 days. In some embodiments, the estrogen and progestin can be
administered for a period of 105 days or 109 days. The first phase
can be, but is not limited to, 14 to 28 days. The second phase can
be, but is not limited to, 35 to 49 days. The third phase can be,
but is not limited to, 35 to 53 days. In some aspects of the
invention, the first phase is 21 days, the second phase is 42 days,
and the third phase is 42 days. In other aspects of the invention,
the first phase is 21 days, the second phase is 42 days, and the
third phase is 46 days.
[0065] In some aspects of the invention, the estrogen and progestin
are administered for a period of 123 to 145 days, of 126 to 144
days, of 129 to 141 days, or of 132 to 138 days. For example, the
estrogen and progestin can be administered for a period of 133 days
to 137 days. In some embodiments, the estrogen and progestin can be
administered for a period of 133 days or 137 days. The first phase
can be, but is not limited to, 35 to 49 days. The second phase can
be, but is not limited to, 42 to 56 days. The third phase can be,
but is not limited to, 35 to 53 days. In some aspects of the
invention, the first phase is 42 days, the second phase is 49 days,
and the third phase is 42 days. In other aspects of the invention,
the first phase is 42 days, the second phase is 49 days, and the
third phase is 46 days.
[0066] In some aspects of the invention, the estrogen and progestin
are administered for a period of 165 to 187 days, of 168 to 186
days, of 171 to 183 days, or of 174 to 180 days. For example, the
estrogen and progestin can be administered for a period of 175 days
to 179 days. In some embodiments, the estrogen and progestin can be
administered for a period of 175 days or 179 days. The first phase
can be, but is not limited to, 35 to 49 days. The second phase can
be, but is not limited to, 56 to 70 days. The third phase can be,
but is not limited to, 63 to 81 days. In some aspects of the
invention, the first phase is 42 days, the second phase is 63 days,
and the third phase is 70 days. In other aspects of the invention,
the first phase is 42 days, the second phase is 63 days, and the
third phase is 74 days.
[0067] In some aspects of the invention, the estrogen and progestin
are administered for a period of 180 to 369 days, of 347 to 369
days, of 350 to 366 days, of 353 to 363 days, or of 356 to 362
days. For example, the estrogen and progestin can be administered
for a period of 357 days to 361 days. In some embodiments, the
estrogen and progestin can be administered for a period of 357 days
or 361 days. The first phase can be, but is not limited to, 49 to
63 days. The second phase can be, but is not limited to, 168 to 182
days. The third phase can be, but is not limited to, 119 to 137
days. In some aspects of the invention, the first phase is 56 days,
the second phase is 175 days, and the third phase is 126 days. In
other aspects of the invention, the first phase is 56 days, the
second phase is 175 days, and the third phase is 130 days. In some
aspects of the invention, the estrogen and progestin are
administered in four or more phases.
[0068] In some aspects of the invention, the method of providing an
ascending-dose extended cycle regimen further includes a
hormone-free period. The hormone-free period can be, but is not
limited to, 2 to 10 consecutive days. The hormone-free period can
be 2 to 8 consecutive days. For example, the hormone-free period
can be 3, 5 or 7 days. The hormone-free period can be a
non-administration or administration of a placebo. The hormone-free
period can include administration of other active ingredients.
[0069] In some aspects of the invention, the method of providing an
ascending-dose extended cycle regimen further comprises
administering estrogen for a period of 2 to 10 consecutive days
("unopposed estrogen interval"). The unopposed estrogen interval
can be for a period of 2 to 8 consecutive days. For example,
administration of an ascending-dose extended cycle regimen can be
followed by administration of the estrogen for a period of 3, 5 or
7 days. The unopposed estrogen interval can include administration
of other active ingredients.
[0070] Examples of other additional pharmaceutically active
ingredients or agents include, but are not limited to, vitamin D or
vitamin D analogues; one or more of the B complex vitamins, such as
vitamin B3 (niacin (i.e., nicotinic acid and/or nicotinamide)),
vitamin B9 (folic acid or folate), vitamin B6 and/or vitamin B12;
minerals such as, for example, calcium; iron (e.g., ferrous iron,
such as, e.g., ferrous sulfate, ferrous fumarate, ferrous
gluconate, or an iron glycine amino acid chelate); agents for
preventing and treating bone conditions such as bisphosphonates
(e.g., alendronate), teriparatide (e.g., FORTEO.TM.), and SERMs
(selective estrogen receptor modulators, e.g., raloxifene).
[0071] These additional active agents can be administered during
the period of administration of estrogen and progestin, the
hormone-free period, the unopposed estrogen interval, or a
combination of these periods. For example, vitamin D and/or calcium
or a bisphosphonate can be administered during the hormone-free
period as a method of maintaining or preventing loss of bone
density. Suitable forms of vitamin D and of calcium and
bisphosphonate would be known to those of skill in the art. The
active ingredients can be provided in the same, different, or
separate dosage forms.
[0072] In some aspects of the invention, the estrogen that is
administered for a period of, e.g., 2 to 10 consecutive days is in
a daily dosage that is the equivalent of 5 .mu.g to 50 .mu.g, 5
.mu.g to 30 .mu.g, or 10 .mu.g of ethinyl estradiol.
[0073] The ascending-dose extended cycle regimens are optionally
administered with an antidepressant. In some aspects of the
invention, the antidepressant is administered in combination with
estrogen during the unopposed estrogen interval of the regimen. In
other aspects of the invention, the antidepressant is administered
continuously throughout the regimen, or, in yet other aspects of
the invention, the antidepressant is administered intermittently.
For example, in some aspects of the invention, the antidepressant
is administered intermittently during the late luteal phase, which
is typically one to two weeks before menses. In yet other aspects
of the invention, the antidepressant is administered one time
during a menstrual cycle, or once weekly. For example, in some
aspects of the invention, fluoxetine hydrochloride is administered
in a one-time or once-weekly dose of about 90 mg. In other aspects
of the invention, the antidepressant is administered during the
hormone-free period.
[0074] The antidepressant that is optionally combined with the
ascending-dose extended cycle regimens can be a selective serotonin
reuptake inhibitor (SSRI), a selective serotonin and norepinephrine
reuptake inhibitor (SSNRI), a tricyclic antidepressant or
anxiolytic, or any antidepressant known to one of skill in the art.
Suitable antidepressants include, but are not limited to,
alprazolam (XANAX.RTM.), clomipramine (ANAFRANIL.RTM.), fluoxetine
(PROZAC.RTM.), paroxetine (PAXIL.RTM.), sertraline (ZOLOFT.RTM.),
nefazodone (SERZONE.RTM.), fenfluramine (PONDIMIN.RTM.) and
venlafaxine (EFFEXOR.RTM.).
[0075] The daily amount of antidepressant administered can vary,
depending on the antidepressant used, from about 0.75 to about 2
mg, from about 10 to about 20 mg, or from about 50 to about 100 mg.
For example, in some aspects of the invention, fluoxetine
hydrochloride is administered in a daily amount of about 5 mg to
about 120 mg. A suitable daily amount of antidepressant for
administration can be determined by one of skill in the art, e.g.,
a physician.
[0076] Thus, in some aspects of the invention, the method of
providing an ascending-dose extended cycle regimen further
comprises administering an antidepressant. The antidepressant can
be administered (i) during a hormone-free period, (ii) in
combination with an estrogen for a period of, e.g., 2 to 10
consecutive days, (iii) continuously, (iv) intermittently, (v) one
time, or (vi) once weekly. In some aspects of the invention, the
antidepressant is a SSRI such as fluoxetine. In other aspects of
the invention, the antidepressant is a SSNRI.
[0077] In some aspects of the invention, the administration of an
ascending-dose extended cycle regimen of the present invention is
followed by monophasic administration of an estrogen and a
progestin. As used herein, "monophasic" refers to the continuous
use of one particular dose of an estrogen and a progestin during
the period of administration of the dosage form of the estrogen and
progestin. In some aspects of the invention, the administration of
an ascending-dose extended cycle regimen is followed by monophasic
administration of an estrogen and a progestin continuously. In some
aspects of the invention, the administration of an ascending-dose
extended cycle regimen is followed by monophasic administration of
an estrogen and a progestin for a period of greater than 30 or 31
consecutive days.
[0078] In some aspects of the invention, the administration of an
ascending-dose extended cycle regimen is followed by monophasic
administration of an estrogen and a progestin for a period of 350
to 370 consecutive days, of 260 to 280 consecutive days, of 175 to
190 consecutive days, or of 60 to 110 consecutive days. The
monophasic administration of an estrogen and a progestin can be
optionally followed either by a hormone-free period of, e.g., 2 to
10 consecutive days or by administration of estrogen for a period
of, e.g., 2 to 10 consecutive days.
Treatment of Conditions and Disorders
[0079] An ascending-dose extended cycle regimen disclosed herein
can be used as a method of female contraception. Thus, the
invention is directed to a method of contraception in a female in
need thereof by administering to the female an ascending-dose
extended cycle regimen disclosed herein. The female can be, for
example, of childbearing age or peri-menopausal.
[0080] However, an ascending-dose extended cycle regimen is also
useful as a method of treating a variety of conditions and
disorders in females. Thus, an ascending-dose extended cycle
regimen can be used as a method of providing contraception to a
female for the treatment of a condition or disorder, or as a method
of providing contraception and treating a condition or disorder in
a female. Such conditions and disorders are described below and
include, but are not limited to: breakthrough bleeding; irregular
withdrawal bleeding; menstrual bleeding disorders; symptoms
associated with an ovarian cyst, uterine leiomyoma (fibroid tumor),
and Polycystic Ovarian Syndrome; hirsutism; iron deficiency anemia;
menstrual disorders; acne; endometriosis; endometrial cancer;
ovarian cancer; benign breast disease; infections; ectopic
pregnancy; temporomandibular disorder; catamenial symptoms;
non-menstrual related headache, nausea, and depression;
peri-menopausal symptoms; hypoestrogenism; menopausal disorders;
and loss of bone density.
[0081] The invention, therefore, is also directed to a method of
providing contraception to a female for the treatment of a
condition or disorder, wherein the female is in need of treatment
for the condition or disorder, by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, of childbearing age, peri-menopausal, or
menopausal.
[0082] The invention is also directed to a method of providing
contraception and treating a condition or disorder in a female,
wherein the female is in need of both contraception and treatment
of the condition or disorder, by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, of childbearing age or peri-menopausal.
[0083] An ascending-dose extended cycle regimen disclosed herein
includes administration to a female beginning at Day 1 of a
menstrual cycle that is defined as beginning at the first day of
menstrual flow. Alternatively, an ascending-dose extended cycle
regimen disclosed herein can also include administration to a
female beginning at Day 1 of a menstrual cycle that is defined as
beginning with the day after the ending of the menstrual flow.
Alternatively, an ascending-dose extended cycle regimen disclosed
herein also can include administration to a female beginning at Day
1 of a menstrual cycle that is defined as beginning with any day
within the menstrual cycle.
[0084] For each of the disclosed methods of the invention, the
effect of administration of an ascending-dose extended cycle
regimen, with respect to the specified condition (e.g., inducing
the specified condition in the female, reducing the occurrence of
the condition, minimizing the condition, or treating the condition
or disorder) can be evaluated in comparison to each other, to the
condition or disorder exhibited by the female after administration
of a conventional or standard 28-day contraceptive regimen, after
administration of an extended cycle contraceptive regimen other
than an ascending-dose extended cycle regimen of the present
invention, and/or with no contraceptive regimen. For example, the
effect of administering an ascending-dose extended cycle regimen to
treat a menstrual bleeding disorder can be evaluated by comparing
the occurrence and/or severity of the bleeding disorder in females
suffering from the disorder who have been administered an
ascending-dose extended cycle regimen with the occurrence and/or
severity of the bleeding disorder in females suffering from the
disorder who have not been treated with a contraceptive regimen, or
with females suffering from the disorder who have been administered
a contraceptive regimen not disclosed in the present invention. The
effect of administering an ascending-dose extended cycle regimen of
the invention can also be evaluated by comparing the occurrence
and/or severity of a condition in a female before and after
administration of an ascending-dose extended cycle regimen of the
invention, or by evaluating the condition of the female during the
course of one or more cycles.
[0085] The present invention is directed to a method of reducing
breakthrough bleeding in a female in need thereof by administering
to the female an ascending-dose extended cycle regimen disclosed
herein. The female can be, for example, of childbearing age or
peri-menopausal.
[0086] The invention is also directed to a method of providing
contraception and reducing breakthrough bleeding in a female in
need thereof by administering to the female an ascending-dose
extended cycle regimen disclosed herein. For example, the female
can be of childbearing age or peri-menopausal.
[0087] The invention is directed to a method of inducing regular,
predictable withdrawal bleeding in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age or peri-menopausal. Administration of an
ascending-dose extended cycle regimen is useful in controlling
menstrual cycles in a female by inducing regular, predictable
withdrawal bleeding. By suppressing ovulation and delivering
estrogen and progesterone in a programmed fashion, an
ascending-dose extended cycle regimen can establish or restore
synchrony to the endometrium. This is particularly useful in the
treatment of heavy or intermenstrual bleeding. The resulting
predictable timing and shorter duration of bleeding are especially
advantageous to peri-menopausal women, who often experience
irregular menstrual cycles.
[0088] The invention is also directed to a method of providing
contraception and inducing regular, predictable withdrawal bleeding
in a female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, a female of childbearing age or a
peri-menopausal female.
[0089] The invention is directed to a method of reducing frequency
or delaying onset of a menstrual cycle in a female in need of
delayed or reduced menstruation by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, of childbearing age or peri-menopausal. For
example, particular groups or subpopulations of women can benefit
from reduced menstruation, such as women enlisted in the U.S.
military and women athletes. Control of the menstrual cycle, or
even induction of amenorrhea using an ascending-dose extended cycle
regimen, can be an advantage for women on active duty. The
non-contraceptive benefits resulting from use of an ascending-dose
extended cycle regimen, such as reduction in dysmenorrhea,
premenstrual syndrome, menorrhagia, iron deficiency anemia, and
ability to control timing of withdrawal bleeding, can be desirable
and advantageous to women athletes as well. The term "amenorrhea"
refers to the absence of bleeding during one or more menstrual
cycles of a female. The term encompasses the absence of bleeding
and/or spotting during the unopposed estrogen interval of an
ascending-dose extended cycle regimen of the present invention when
administered to a female, as well as the absence of bleeding or
spotting throughout an entire menstrual cycle during administration
of an ascending-dose extended cycle regimen.
[0090] The invention is also directed to a method of providing
contraception and reducing frequency or delaying onset of a
menstrual cycle in a female in need thereof by administering to the
female an ascending-dose extended cycle regimen disclosed herein.
The female can be, for example, a female of childbearing age or a
peri-menopausal female.
[0091] The invention is directed to a method for minimizing uterine
bleeding in a female in need thereof by administering to the female
an ascending-dose extended cycle regimen disclosed herein. The
female can be, for example, of childbearing age or peri-menopausal.
By diminishing endometrial proliferation, administration of an
estrogen and a progestin in an ascending-dose extended cycle
regimen can reduce the volume and duration of menstrual flow. A
female on a disclosed ascending-dose extended regimen can
experience fewer total scheduled days of bleeding than a female on
a traditional 28-day regimen, and can experience less blood loss,
because an ascending-dose extended cycle regimen involves fewer
stop/start transitions per year. The female to be treated can
exhibit abnormal uterine bleeding, including, for example,
menorrhagia. As used herein, "abnormal uterine bleeding" refers to
an abnormal duration of bleeding (i.e., greater than 7 days of
bleeding, or hypermenorrhea), abnormal amount of bleeding (i.e.,
greater than about 80 mL blood loss during menses, or menorrhagia),
increased frequency of bleeding (i.e., less than 22 days between
menstrual cycles, or polymenorrhea), or any combinations
thereof.
[0092] The invention is also directed to a method of providing
contraception and minimizing uterine bleeding in a female in need
thereof by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The female can be, for example, a
female of childbearing age or a peri-menopausal female.
[0093] The invention, moreover, is directed to a method of treating
a menstrual bleeding disorder in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age or peri-menopausal.
[0094] The invention is also directed to a method of providing
contraception and treating a menstrual bleeding disorder in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, a female of childbearing age or a
peri-menopausal female.
[0095] The invention is directed to a method of treating symptoms
associated with ovarian cysts, uterine leiomyomas (fibroids), or
Polycystic Ovarian Syndrome in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age, peri-menopausal, or menopausal. The invention is
also directed to a method of providing contraception and treating
symptoms associated with ovarian cysts, uterine leiomyomas
(fibroids), or Polycystic Ovarian Syndrome in a female in need
thereof by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The female can be, for example, a
female of childbearing age or peri-menopausal.
[0096] Ovarian cysts, uterine leiomyomas (fibroids), or Polycystic
Ovarian Syndrome can cause symptoms including, but not limited to,
pelvic pain, dysmenorrhea, abnormal uterine bleeding, acne, and
hirsutism. In the invention, such symptoms can be treated by
administration of an ascending-dose extended cycle regimen
described herein.
[0097] Ovarian cysts arise from functional cysts that commonly
occur around mid-cycle, when a follicle destined to become an egg
fails to mature. Instead of leaving the ovary in a process known as
ovulation, it remains inside, floating in a tiny sac of fluid. It
is that sac that eventually forms into a cyst. Although rarely
malignant, ovarian cysts lead to 200,000 hospitalizations in the
United States each year. For some women, some studies have shown
that the cysts develop cycle after cycle. Though ovarian cysts can
sometimes be asymptomatic, they can also cause pain (constant
pelvic pain, pain during intercourse, pain during pelvic movement,
and/or pain before or after menses), abnormal bleeding (lengthened,
shortened, irregular and/or absent menses), and/or abdominal
bloating or distension.
[0098] Uterine fibroids are benign growths of uterine muscle that
sometimes exist singly, but most often are multiple and range in
size from microscopic to filling most of the lower abdominal
cavity. Many women with fibroids have no symptoms at all. For those
that do, the most common complaints are pressure symptoms and
heavy, prolonged periods. There may be pressure in the pelvic
region from the enlarged uterus, and the resulting symptoms are
often related to where the fibroid is exerting pressure (e.g.,
increased urinary frequency, constipation or difficulty with bowel
movements). The pressure can also cause backache, lower abdominal
discomfort, and pain during and after intercourse. Fibroids can
cause very heavy and prolonged periods, leading to iron-deficiency
anemia, as well as painful periods (secondary dysmenorrhea). The
presence of fibroids can also cause reproductive problems such as
infertility, multiple miscarriages, premature labor, or labor
complications.
[0099] The term "ovarian cyst" as used above represents more
singular occurrences caused by the failure of an egg to mature.
Polycystic Ovarian Syndrome (PCOS), in contrast, is due to an
abnormal production of LH (luteinizing hormone) and FSH (follicle
stimulating hormone) by the pituitary gland. An imbalance of these
hormones stops egg production and increases production of
androgens, with the ovaries producing higher levels of testosterone
and estrogens. This results in ovaries "peppered" with empty egg
follicles that become inflamed cysts, irregular or stopped periods
(which in turn causes infertility), excess body hair growth, and
acne on the face and body. PCOS often leads to obesity, diabetes
and hypertension.
[0100] Polycystic Ovarian Syndrome is the cause of most cases of
androgen-dependent hirsutism. See Rittmaster, R. S., Lancet
349:191-195 (1997). Hirsutism can be described as the growth of
excessive hair in women on parts of the body where excessive hair
is generally not present, e.g., on the back and chest. Most cases
of hirsutism are androgen-dependent, i.e., result from a
combination of increased androgen production by the body and
increased skin sensitivity to androgens. Normally, small quantities
of androgens are produced by the ovaries and the adrenal glands.
However, in women suffering from Polycystic Ovarian Syndrome,
androgen levels are elevated, which can lead to the development of
androgen-dependent conditions such as, for example, pronounced
forms of acne (e.g., acne papulopustulosa), androgenetic alopecia
and mild forms of hirsutism. Oral contraceptives can suppress the
ovarian production of androgens and are thus useful in the
treatment of these androgen-dependent conditions.
[0101] Thus, the invention is also directed to a method of treating
hirsutism in a female in need thereof, by administering to the
female an ascending-dose extended cycle regimen disclosed herein.
The female can be, for example, of childbearing age,
peri-menopausal, or menopausal.
[0102] The invention is also directed to a method of providing
contraception and treating hirsutism in a female in need thereof,
by administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, a female
of childbearing age or peri-menopausal.
[0103] The invention is directed to a method of treating alopecia
in a female in need thereof, by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, of childbearing age, peri-menopausal, or
menopausal. The invention is also directed to a method of providing
contraception and treating alopecia in a female in need thereof, by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, a female
of childbearing age or peri-menopausal.
[0104] The invention is further directed to a method of decreasing
risk of iron deficiency anemia in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age or peri-menopausal. A reduction in the volume and
duration of menstrual flow that can result from administration of,
e.g., an ascending-dose extended cycle regimen can lead to a
reduction in the total loss of blood, thus improving the body's
iron stores and reducing the morbidity associated with menorrhagia.
This effect is particularly desirable in women with coagulation
disorders, for example, von Willebrand's disease. The female to be
treated can be, but is not limited to, a peri-menopausal
female.
[0105] The invention is also directed to a method of providing
contraception and decreasing risk of iron deficiency anemia in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, a female of childbearing age or a
peri-menopausal female.
[0106] The invention is directed to a method of treating a
menstrual disorder in a female in need thereof by administering to
the female an ascending-dose extended cycle regimen disclosed
herein. The female can be, for example, of childbearing age or
peri-menopausal. Menstrual disorders include, but are not limited
to, irregular menstrual cycles, dysmenorrhea (painful
menstruation), mittelschmerz, and dysfunctional uterine bleeding,
as well as premenstrual symptoms such as, but not limited to, those
associated with premenstrual syndrome (PMS) or Premenstrual
Dysphoric Disorder (PMDD).
[0107] The invention is also directed to a method of providing
contraception and treating a menstrual disorder in a female in need
thereof by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The female can be, for example, a
female of childbearing age or a peri-menopausal female.
[0108] During the luteal phase of the menstrual cycle, as many as
75% of women with regular menstrual cycles experience some symptoms
of premenstrual syndrome (PMS), a recurring, cyclical disorder
involving behavioral, emotional, social and physical symptoms
(Steiner et al., Annu. Rev. Med. 48:447-455 (1997)). Behavioral,
emotional and social symptoms include, but are not limited to,
irritability, mood swings, depression, hostility and social
withdrawal. Physical symptoms include, but are not limited to,
bloating, breast tenderness, myalgia, migraines or headaches, and
fatigue. True PMS only occurs during the luteal phase of the
menstrual cycle, with a symptom-free period during the follicular
phase. The etiology of PMS is still unknown.
[0109] A subgroup of women with PMS, about 2-9%, exhibit symptoms
that are primarily related to a severe mood disorder. In these
women, the diagnosis of Premenstrual Dysphoric Disorder (PMDD),
which is defined in the Fourth edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) can be applied.
According to the DSM-IV, a woman with PMDD must have at least five
premenstrual symptoms during the luteal phase, with at least one of
the symptoms being an emotional or "core" symptom. The core
symptoms must be irritability, anger, mood swings, tension or
depression (and interfere with daily activities), and must be
confirmed by a prospective daily rating for at least two cycles.
Three to five percent of women with PMS report to have PMDD. There
is also a subgroup of women who experience severe PMS, which
accounts for about 20% of the PMS population. These women
experience severe emotional symptoms that do not fall under the
strict criteria of PMDD as defined in DSM-IV but require medical
attention. U.S. application Ser. No. 10/309,313 relates to the use
of estrogen/progestin contraceptive regimens optionally combined
with an antidepressant for the treatment of PMS, PMDD, and related
conditions.
[0110] Suppression of ovulation that can result from administration
of the extended cycle regimen can also eliminate mid-cycle pain
("mittelschmerz") associated with rupture of the ovarian follicle.
Additionally, suppression of ovulation and delivery of estrogen and
progesterone in a regular, predictable schedule, which can result
from use of an ascending-dose extended cycle regimen can be
beneficial in the treatment of other menstrual disorders such as
heavy or intermenstrual bleeding. In some aspects of the invention,
the female can be a peri-menopausal female.
[0111] The invention is directed to a method of treating acne in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, of childbearing age, peri-menopausal, or
menopausal. An ascending-dose extended cycle regimen may suppress
gonadotropin and decrease ovarian and adrenal androgen production,
resulting in an improvement in acne of, e.g., women of childbearing
age and older.
[0112] The invention is also directed to a method of providing
contraception and treating acne in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, a female
of childbearing age or peri-menopausal.
[0113] The invention is directed to a method of treating
endometriosis in a female in need thereof by administering to the
female an ascending-dose extended cycle regimen disclosed herein.
The female can be, for example, of childbearing age or
peri-menopausal. The invention is also directed to a method of
providing contraception and treating endometriosis in a female in
need thereof by administering to the female an ascending-dose
extended cycle regimen disclosed herein. The female can be, for
example, a female of childbearing age or a peri-menopausal
female.
[0114] In hormonal therapy of endometriosis, endometriotc tissue
responds to adverse endocrine environments (low estrogen and/or
high progestin concentration). Progestins produce marked atrophy of
the endometrium and ectopic endometrial tissue and decrease
intraperitoneal inflammation associated with endometriosis. The
American College of Obstetrics and Gynecology stated that
progestins, alone or in combination with estrogens as oral
contraceptives, are an optimal choice for the management of
endometriosis in women who desire contraception (American College
of Obstetricians and Gynecologists, ACOG Practice Bulletin No. 11
(December 1999)). The use of an ascending-dose extended cycle
regimen of the present invention can be beneficial for treating or
preventing endometriosis.
[0115] Chronic pelvic pain often precedes and is associated with
the development of endometriosis. Thus, the invention is also
directed to a method of treating chronic pelvic pain in a female in
need thereof by administering to the female an ascending-dose
extended cycle regimen disclosed herein. The female can be, for
example, of childbearing age or peri-menopausal. The invention is
also directed to a method of providing contraception and treating
chronic pelvic pain in a female in need thereof by administering to
the female an ascending-dose extended cycle regimen disclosed
herein. The female can be, for example, a female of childbearing
age or a peri-menopausal female.
[0116] The invention is further directed to a method of reducing
the risk of endometrial cancer in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen, disclosed herein. The female can be, for example, of
childbearing age, peri-menopausal, or menopausal. The invention is
also directed to a method of providing contraception and reducing
the risk of endometrial cancer in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, a female
of childbearing age or peri-menopausal.
[0117] The invention is directed to a method of reducing the risk
of ovarian cancer in a female in need thereof by administering to
the female an ascending-dose extended cycle regimen disclosed
herein. The female can be, for example, of childbearing age,
peri-menopausal, or menopausal. The frequency of ovulation and
thereby the frequency of ovarian stimulation can be reduced,
suppressed, or eliminated by use of an ascending-dose extended
cycle regimen. The invention is also directed to a method of
providing contraception and reducing the risk of ovarian cancer in
a female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, a female of childbearing age, peri-menopausal,
or menopausal.
[0118] The invention is further directed to a method of treating
benign breast disease, including, but not limited to, fibrocystic
breast disease, in a female in need thereof by administering to the
female an ascending-dose extended cycle regimen disclosed herein.
The female can be, for example, of childbearing age,
peri-menopausal, or menopausal. About a third of all women between
the ages of 30 and 50 will be diagnosed with fibrocystic breast
disease or other benign breast condition. Other terms for this
condition include chronic mastitis (inflammation) and mammary
dysplasia.
[0119] The invention is also directed to a method of providing
contraception and treating benign breast disease in a female in
need thereof by administering to the female an ascending-dose
extended cycle regimen disclosed herein. The female can be, for
example, a female of childbearing age or peri-menopausal.
[0120] The invention is also directed to a method of reducing the
risk of colorectal cancer in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age, peri-menopausal, or menopausal. An ascending-dose
extended cycle regimen of the present invention is thought to
protect against colorectal cancer as a result of changes in bile
synthesis and secretion due to the female hormones in the regimen,
which is thought to lead to a reduced concentration of bile acids
in the colon. It has also been observed that estrogen inhibits the
growth of colon cancer cells in vitro, and estrogen receptors have
been identified in normal and neoplastic colon epithelial cells.
See Fernandez, E., et al., British J. Cancer 84:722-727 (2001).
Thus, an ascending-dose extended regimen can be beneficial in the
prevention or reduction in the occurrence of colorectal cancer.
[0121] The invention is also directed to a method of providing
contraception and reducing the risk of colorectal cancer in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, a female of childbearing age or
peri-menopausal.
[0122] The invention is directed to a method of preventing or
treating an infection in a female in need thereof by administering
to the female an ascending-dose extended cycle regimen disclosed
herein. The female can be, for example, of childbearing age,
peri-menopausal, or menopausal. For example, sexually transmitted
diseases (STDs) are infections caused by a pathogen such as a
virus, bacterium, parasite, or fungus, that is spread from person
to person through sexual contact. STDs can be painful, irritating,
and even life-threatening. An ascending-dose extended cycle regimen
is believed to have a protective role against the development of
some STDs because it stimulates the body to produce a thicker
cervical mucous, which acts as a barrier to semen carrying bacteria
that cause sexually transmitted diseases.
[0123] The invention is also directed to a method of providing
contraception and treating an infection in a female in need thereof
by administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, but is not limited to,
a female of childbearing age or peri-menopausal.
[0124] Pelvic Inflammatory Disease (PID) is a complication that can
result from STD infections. PID is a serious syndrome of the female
reproductive tract that results from the spread of infections (most
often sexually transmitted infections such as Chlamydia trachomatis
and Nisseris gonnorrheoea) from the vagina and endocervix to the
uterus, fallopian tubes and ovaries. PID is commonly manifested as
endometritis (infection of the lining of the uterus) or salpingitis
(infection of the fallopian tubes), and less commonly as pelvic
peritonitis and/or inflammation of contiguous structures.
(MacDonald, N. E., and Bowie, W. R., Canadian Communicable Disease
Report 21S4: 25-33 (1995); Westrom, L. and Mardh, P-A., Sexually
Transmitted Diseases, 2.sup.nd Ed., pages 593-613, New York:
McGraw-Hill, 1990).
[0125] PID is a major cause of infertility and ectopic pregnancy.
Ectopic pregnancy results from the implantation of a fertilized
ovum in the fallopian tube or in the abdominal cavity and is
thought to be caused by ciliary dysfunction within the fallopian
tube resulting from prior tubal infection with N. gonorrhoea and/or
C. trachomatis, which often results in loss of ciliated epithelial
cells from the fallopian tubes. It has been estimated that prior
tubal infection with STD agents causes about 50% of the cases of
ectopic pregnancy. (MacDonald, N. E., and Brunham, R., Canadian
Journal of Human Sexuality 6(2):161-170 (1997).)
[0126] An ascending-dose extended cycle regimen is believed to have
a protective role against the development of PID because it
stimulates the body to produce thicker cervical mucous, which helps
prevent semen carrying STD-causing bacteria from gaining access to
the uterus and eventually causing PID and PID-related
complications, such as ectopic pregnancy.
[0127] Thus, an ascending-dose extended cycle regimen of the
present invention can be useful in the prevention or reduction in
occurrence of sexually transmitted diseases, Pelvic Inflammatory
Disease, and ectopic pregnancy. Accordingly, the invention is
directed to a method of preventing or reducing the occurrence of a
sexually transmitted disease or Pelvic Inflammatory Disease in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The
invention is also directed to a method of preventing ectopic
pregnancy in a female in need thereof by administering to the
female an ascending-dose extended cycle regimen disclosed herein.
The female can be, but is not limited to, a female of childbearing
age or a peri-menopausal female.
[0128] The invention is also directed to a method of providing
contraception and treating a sexually transmitted disease or Pelvic
Inflammatory Disease in a female in need thereof by administering
to the female an ascending-dose extended cycle regimen disclosed
herein. The invention, moreover, is directed to a method of
providing contraception and preventing ectopic pregnancy in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, but is not limited to, a female of childbearing age or a
peri-menopausal female.
[0129] In addition, use of an ascending-dose extended cycle
regimen, in comparison to the use of a conventional 28-day
contraceptive regimen, can lead to a reduction in the reported
occurrences of infection such as urinary tract infections,
pharyngitis, upper respiratory tract infections, and sinusitus.
Thus, the invention is further directed to the prevention or
reduction in occurrence of certain infections, such as urinary
tract infections, pharyngitis, upper respiratory tract infections,
and sinusitus, in a female in need thereof by administering to the
female an ascending-dose extended cycle regimen disclosed herein.
The female can be, for example, of childbearing age,
peri-menopausal, or menopausal. The invention is also directed to a
method of providing contraception and treating certain infections,
such as urinary tract infections, pharyngitis, upper respiratory
tract infections, and sinusitus, in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age or peri-menopausal.
[0130] The invention is also directed to a method of treating
temporomandibular disorder in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age, peri-menopausal, or menopausal. Temporomandibular
disorders (TMD) are disorders of the jaw muscles, temporomandibular
joints, and/or the nerves associated with chronic facial pain. An
ascending-dose extended cycle regimen of the present invention can
be useful in the treatment of TMD. The invention is also directed
to a method of providing contraception and treating
temporomandibular disorder in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, for example, of
childbearing age or peri-menopausal.
[0131] The invention is directed to a method of treating a
catamenial symptom in a female in need thereof by administering to
the female an ascending-dose extended cycle regimen disclosed
herein. The female can be, for example, of childbearing age or
peri-menopausal. Catamenial symptoms are those associated with
conditions, disorders, or diseases that can worsen around the time
of menses. Such conditions, disorders, or diseases include, but are
not limited to, asthma, rheumatoid arthritis, migraine headaches,
seizure disorders or epilepsy, multiple sclerosis, and diabetes.
The invention is also directed to a method of providing
contraception and treating a catamenial symptom in a female in need
thereof by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The female can be, for example, of
childbearing age or peri-menopausal.
[0132] Arthritis is a prevalent chronic condition in women.
Hormonal factors can influence the frequency and severity of
arthritis. In some women, arthritis symptoms such as joint
stiffness, swelling and pain peak during the postovulatory phase of
the menstrual cycle, and cyclic changes in local antibody release,
white blood cell subpopulations and altered pain perception have
been proposed as possible mechanisms (Case, A. M. and Reid, R. L.,
Arch. Intern. Med. 158:1405-1412 (1998)). Estrogen administered as
a single agent, and as part of a combined oral contraceptive has
been reported to benefit some women (Kay, C. R. and Wingrave, S.
J., Lancet 1:1437 (1983); Linos, A., et al., Lancet 1:1871 (1978)).
Thus, use of an ascending-dose extended cycle regimen can be
beneficial as a method of treating a catamenial symptom, such as,
e.g., a symptom associated with rheumatoid arthritis, in a female
in need thereof.
[0133] Approximately 60% of women with migraines report a
relationship to menstruation (Case, A. M. and Reid, R. L., Arch.
Intern. Med. 158:1405-1412 (1998)). Decreasing levels of estrogen
during the late luteal phase of the menstrual cycle or abrupt
withdrawal of estrogen as during the non-administration period in
women taking oral contraceptives are thought to trigger migraine
attacks (Sulak P. J., et al., Obstet. Gynecol 95:261-266 (2000);
Kudrow, L., Headache 15:36-49 (1975); Whitty, C. W. M., et al.,
Lancet 1:856-859 (1966)). Thus, use of an ascending-dose extended
cycle regimen can be beneficial as a method of treating a
catamenial symptom in a female in need thereof, such as, e.g., a
migraine headache in a female.
[0134] Catamenial epilepsy refers to seizure disorders that occur
or worsen around menstruation. It is believed to result from cyclic
alterations in both ovarian hormone levels and drug metabolism
(Case, A. M. and Reid, R. L., Arch. Intern. Med. 158:1405-1412
(1998)). Thus, use of an ascending-dose extended cycle regimen can
be beneficial as a method of treating a catamenial symptom such as,
e.g., a symptom associated with epilepsy, in a female in need
thereof.
[0135] The invention is directed to a method of treating headache
or nausea unrelated to the menstrual cycle in a female in need
thereof by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The female can be, for example, of
childbearing age, peri-menopausal, or menopausal. Use of an
ascending-dose extended cycle regimen, in comparison to the use of
a conventional 28-day contraceptive regimen, can lead to a
reduction in the reported occurrences of non-menstrual-related
headache and nausea. Thus, a disclosed ascending-dose extended
cycle regimen can be used as a method of preventing or treating
non-menstrual-related headache and nausea. The invention is also
directed to a method of providing contraception and treating
headache or nausea unrelated to the menstrual cycle in a female in
need thereof by administering to the female an ascending-dose
extended cycle regimen disclosed herein. The female can be, for
example, of childbearing age or peri-menopausal.
[0136] The invention is directed further to a method of treating
depression unrelated to the menstrual cycle in a female in need
thereof by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The female can be, for example, of
childbearing age, peri-menopausal, or menopausal. "Depression" is a
term that is often used to refer to different forms of depressive
disorders and includes major depression, bipolar disorder
(sometimes called manic-depressive illness), and dysthymia, a less
severe form of depression. Major depression is manifested by a
combination of symptoms that interfere with the ability to work,
study, sleep, eat and enjoy once pleasurable activities. Bipolar
disorder, which is not nearly as prevalent as other forms of
depressive disorders, is characterized by cycling mood changes.
Dysthymia, a less severe type of depression, involves long-term,
chronic symptoms that do not disable, but keep one from functioning
well or from feeling well. "Depression" also includes the less
severe, temporary sadness and loneliness often felt from time to
time. Use of an ascending-dose extended cycle regimen, compared to
use of a conventional 28-day contraceptive regimen, can lead to a
reduction in the reported occurrences of non-menstrual-related
depression. Thus, a disclosed ascending-dose extended regimen can
be used as a method of preventing or treating non-menstrual-related
depression.
[0137] The invention is also directed to a method of providing
contraception and treating depression unrelated to the menstrual
cycle in a female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The female
can be, for example, of childbearing age or peri-menopausal.
[0138] The invention is further directed to a method of increasing
contraceptive effectiveness in a female in need thereof by
administering to the female an ascending-dose extended cycle
regimen disclosed herein. The female can be, but is not limited to,
a female of childbearing age or a peri-menopausal female. A female
in need of contraceptive effectiveness can be, but is not limited
to, a higher weight female. A "higher weight female" refers to a
human female weighing about 70 kg or more or having a body mass
index (BMI) of greater than about 25. In a recent study of body
weight and oral contraceptive failure, women weighing about 70.5 kg
or more were reported to have a 60% higher risk of oral
contraceptive failure (Holt, V. L., et al., Obstet. Gynecol.
99:820-827 (2002)).
[0139] Thus, the invention is directed to a method of increasing
contraceptive effectiveness in a higher-weight female in need
thereof, by administering to the female an ascending-dose extended
cycle regimen disclosed herein. The invention is directed to a
method of increasing the contraceptive effectiveness in a human
female weighing about 70 kg or more, weighing about 80 kg or more,
or weighing about 90 kg or more, by administering to the female an
ascending-dose extended cycle regimen.
[0140] A disclosed ascending-dose extended cycle regimen can also
be used as a method of increasing the contraceptive effectiveness
in a human female with a body mass index of greater than about 25,
greater than about 30, or greater than about 35. Thus, the
invention is also directed to a method of increasing the
contraceptive effectiveness in a human female with a body mass
index of greater than about 25, greater than about 30, or greater
than about 35, by administering to the female an ascending-dose
extended cycle regimen.
[0141] The invention is also directed to a method of increasing
fertility in a female in need thereof, by administering to the
female an ascending-dose extended cycle regimen disclosed herein,
followed by discontinuation of the regimen and optional
administration of an agent to induce ovulation in the female. The
female can be, but is not limited to, a female of childbearing age
or a peri-menopausal female.
[0142] It has been observed clinically that women who are taking
oral contraceptives for anovulation often conceive when pills are
missed, or shortly after discontinuing oral contraceptive
treatment, most likely due to a "rebound effect" occurring in the
ovary at least for a short period of time. Suppression of ovarian
activity using oral contraceptive pills for 2-6 months may result
in decreases in early follicular ovarian androgen production and LH
and estradiol levels. Increased androgen levels have been shown to
have adverse effects on folliculogenesis. These endocrine changes
in the early follicular phase may be responsible for improved
ovarian response to clomiphene or other treatments for anovulatory
infertility. See Brannigan, E. F., and Estes, M. A., Am. J. Obstet.
Gynecol. 188:1424-1430 (2003).
[0143] Examples of agents that induce ovulation, and that can be
administered following discontinuation of an ascending-dose
extended cycle regimen of the present invention, include, but are
not limited to, menotropins (Follicle Stimulating Hormone (FSH) and
Luteinizing Hormone (LH), e.g., Pergonal.RTM.) and chlomiphene
citrate (Clomid.RTM.). The ovulation-inducing agent can be
administered during a suitable time as can be determined by one of
skill in the art, e.g., a physician. In some aspects of the
invention, the ovulation-inducing agent can be administered, e.g.,
within about one week to about one month, or within about one week
to about two weeks, after discontinuation of an ascending-dose
extended cycle regimen of the present invention. In some aspects of
the invention, the ovulation-inducing agent is administered, e.g.,
2 to 10 days, or 5 to 9 days after discontinuation of an
ascending-dose extended cycle regimen.
[0144] Thus, the invention is directed to a method of increasing
fertility in a female in need thereof, the method comprising (i)
administration to the female of an ascending-dose extended cycle
regimen disclosed herein; (ii) discontinuation of administration of
an ascending-dose extended cycle regimen; and (iii) optional
administration to the female of an ovulation-inducing agent during
the discontinuation of administration of an ascending-dose extended
cycle regimen; wherein fertility in the female is increased.
[0145] In some aspects of the invention, the disclosed methods are
particularly useful in peri-menopausal women and/or menopausal
women. Peri-menopausal and menopausal women frequently experience a
large variety of conditions and disorders that have been attributed
to estrogen deprivation due to ovarian failure or hypoestrogenism.
The duration of these disorders can be extremely variable and
include hot flushes which can be devastating in some women and very
mild in others. Dryness of the vagina associated with
susceptibility to minor infections, and frequently associated with
discomfort during intercourse, is another symptom that can be
directly related to the decrease in estrogen availability.
[0146] In a long-term sense, one of the most health-threatening
aspects of menopause is the loss of mineral from bone which can
result in a decrease in bone mass (osteoporosis) and generates a
serious risk of fractures. For example, evidence exists that there
is a six-fold increase in fractures in post-menopausal women as
opposed to men of the same age (Garraway et al., Mayo Clinic
Proceedings 54:701-707 (1979)). These fractures, of course, carry a
high complication rate among older people, a marked increase in
disability and general morbidity, and certainly an increased risk
of mortality.
[0147] Another serious health-threatening aspect of menopause is
the impressive loss of protection against heart attacks, which is
enjoyed by younger women up to the age of 60, when compared to men
of the same age. The steep increase in mean serum cholesterol
concentration, which occurs around menopause (during the fourth and
fifth decades), can contribute importantly to the progressive
increase in death from ischemic heart disease in older women. In
the eighth and ninth decades, the incidence of deaths from ischemic
heart disease, approaches that of men (Havlik, R. J. and
Manning-Feinleid, P. H., NIH Publication No. 79-1610, U.S.
Department of HEW (1979)).
[0148] Accordingly, the invention is directed to a method for
treating conditions, such as the physical conditions described
above, resulting from menopausal estrogen decline in a menopausal
female by administering an ascending-dose extended cycle regimen
disclosed herein to the female. The invention is also directed to a
method for treating conditions, such as the physical conditions
described above, resulting from hypoestrogenism in a female by
administering an ascending-dose extended cycle regimen disclosed
herein to the female. The invention is further directed to a method
for treating conditions, such as the physical conditions described
above, resulting from ovarian failure in a female by administering
an ascending-dose extended cycle regimen disclosed herein to the
female.
[0149] The invention is also directed to a method of providing
contraception and treating conditions, such as the physical
conditions described above, resulting from hypoestrogenism in a
peri-menopausal female in need thereof by administering an
ascending-dose extended cycle regimen disclosed herein to the
peri-menopausal female. The invention is further directed to a
method of providing contraception and treating conditions, such as
the physical conditions described above, resulting from ovarian
failure in a peri-menopausal female in need thereof by
administering an ascending-dose extended cycle regimen disclosed
herein to the peri-menopausal female.
[0150] In addition to the above-mentioned major physical problems,
some menopausal and peri-menopausal women experience a large
variety of other symptoms ranging from depression, insomnia, and
nervousness, to symptoms of arthritis and so forth.
[0151] It is generally agreed that estrogen is the most effective
agent for the control or prevention of menopausal flushes and
vaginal atrophy. It is effective in retarding or preventing the
appearance of clinical evidence of osteoporosis. In appropriate
doses, when combined with progestin, a favorable effect upon blood
lipids can also be seen. Problems with estrogen therapy do exist,
however, and have been widely explored and documented in the
medical literature. The means by which estrogen has been
administered, generally speaking, involves either the use of
estrogen alone or estrogen plus a progestin.
[0152] Estrogen alone, given in small doses on a continuous basis,
is effective in most patients for the control of the above symptoms
and problems associated therewith. However, although the vast
majority of women taking continuous low-dose estrogen will not have
bleeding for many months or even years, there is a distinct risk
posed by this routine of silently (i.e., exhibiting no overt
symptoms) developing "hyperplasia of the endometrium." This term
refers, of course, to an overstimulation of the lining of the
uterus which can become pre-malignant, coupled with the possibility
that the patient will eventually develop cancer of the uterine
lining even under such a low-dose regimen (Gusberg et al.,
Obstetrics and Gynecology 17:397-412 (1961)).
[0153] Estrogen alone can also be given in cycles, usually 21-25
days on treatment and 5-7 days off treatment. Again, if small doses
of estrogen are required to control the symptoms and it is used to
this fashion, only about 10% of women will experience withdrawal
bleeding between the cycles of actual treatment. However, one must
again be concerned by the risk of developing endometrial
hyperplasia and by the increased relative risk of developing cancer
of the uterus (Research on the Menopause: Report of a W.H.O.
Scientific Group, 53-68 (1981)).
[0154] The addition of progestin with estrogen, however, as in an
ascending-dose extended cycle disclosed herein, will virtually
eliminate the concern about developing endometrial hyperplasia and
reduce the risk of developing endometrial carcinoma below that of
the untreated general population.
[0155] Thus, the invention is directed to a method of treating a
menopausal disorder or a peri-menopausal disorder or symptom in a
female in need thereof by administering to the female an
ascending-dose extended cycle regimen disclosed herein. The
invention is also directed to a method of providing contraception
and treating a peri-menopausal disorder or symptom in a
peri-menopausal female in need thereof by administering to the
female an ascending-dose extended cycle regimen disclosed
herein.
[0156] An ascending-dose extended cycle regimen can be used as a
method of maintaining bone density or preventing loss of bone
density in a female. An ascending-dose extended cycle regimen can
also be used in this way by administering calcium and/or vitamin D,
e.g., in combination with the administration of an estrogen and a
progestin.
[0157] An ascending-dose extended cycle regimen is not limited to
administration to peri-menopausal or menopausal females as a method
of maintaining bone density or preventing bone loss. An
ascending-dose extended cycle regimen can also be used in a method
of maintaining bone density or preventing bone loss by
administration to a female of childbearing age that is not
peri-menopausal or menopausal. For example, an ascending-dose
extended cycle regimen can be used with females 12-16 years of age
who have not yet achieved peak bone density, but who, due to
various conditions such as anorexia, are at risk of loss of bone
density or at risk of not achieving a normal physiologic bone
density for age and developmental maturity.
[0158] Thus, an ascending-dose extended cycle regimen can also be
used as a method of treating a condition resulting from menopausal
or peri-menopausal estrogen decline, including osteoporosis. An
ascending-dose extended cycle regimen can also be used as a method
of providing contraception and treating a condition in a
peri-menopausal female in need thereof resulting from
peri-menopausal estrogen decline, including osteoporosis.
[0159] An ascending-dose extended cycle regimen can also be used as
a method of treating a female in need of hormone replacement
therapy.
Modes of Administration and Compositions
[0160] The estrogen and/or progestin are administered in the
conventional manner by any route where they are active. For
example, administration can be by, but is not limited to, oral,
parenteral, subcutaneous, intravenous, intramuscular,
intraperitoneal, transdermal, buccal, or ocular routes, or
intravaginally, by inhalation, by depot injections, or by hormone
implants. Thus, the dosage forms for the estrogen and/or progestin
(either alone or in combination with other pharmaceuticals) can be,
but are not limited to, sublingual, injectable (including
short-acting, depot, implant and pellet forms injected
subcutaneously or intramuscularly), vaginal creams, suppositories,
pessaries, rings, rectal suppositories, intrauterine devices, and
transdermal forms such as patches and creams.
[0161] Thus, pharmaceutical compositions containing the estrogen
and/or progestin and a suitable carrier can be solid dosage forms
which include, but are not limited to, tablets, capsules, cachets,
pellets, pills, powders and granules; topical dosage forms which
include, but are not limited to, solutions, powders, fluid
emulsions, fluid suspensions, semi-solids, ointments, pastes,
creams, gels and jellies, and foams; and parenteral dosage forms
which include, but are not limited to, solutions, suspensions,
emulsions, and dry powder. It is known in the art that the active
ingredients can be contained in such compositions with
pharmaceutically acceptable diluents, fillers, disintegrants,
binders, lubricants, surfactants, hydrophobic vehicles, water
soluble vehicles, emulsifiers, buffers, humectants, moisturizers,
solubilizers, preservatives and the like. The means and methods for
administration are known in the art and an artisan can refer to
various pharmacologic references for guidance. For example, "Modern
Pharmaceutics", Banker & Rhodes, Marcel Dekker, Inc. 1979; and
"Goodman & Gilman's The Pharmaceutical Basis of Therapeutics,"
6.sup.th Edition, MacMillan Publishing Co., New York 1980 can be
consulted.
[0162] For oral administration, the estrogen and/or progestin can
be formulated readily by combining these compounds with
pharmaceutically acceptable carriers well known in the art. Such
carriers enable the compounds of the invention to be formulated as
tablets, pills, dragees, capsules, liquids, gels, syrups, slurries,
suspensions and the like, for oral ingestion by a patient to be
treated. Pharmaceutical preparations for oral use can be obtained
by adding a solid excipient, optionally grinding the resulting
mixture, and processing the mixture of granules, after adding
suitable auxiliaries, if desired, to obtain tablets or dragee
cores. Suitable excipients include, but are not limited to, fillers
such as sugars, including, but not limited to, lactose, sucrose,
mannitol, and sorbitol; cellulose preparations such as, but not
limited to, maize starch, wheat starch, rice starch, potato starch,
gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and
polyvinylpyrrolidone (PVP). If desired, disintegrating agents can
be added, such as, but not limited to, the cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
alginate.
[0163] The pharmaceutical compositions of the estrogen and/or
progestin also can comprise suitable solid or gel phase carriers or
excipients such as calcium carbonate, calcium phosphate, various
sugars, starches, cellulose derivatives, gelatin, and polymers such
as, e.g., polyethylene glycols.
[0164] Dragee cores can be provided with suitable coatings. For
this purpose, concentrated sugar solutions can be used, which can
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments can be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0165] Pharmaceutical preparations which can be used orally
include, but are not limited to, push-fit capsules made of gelatin,
as well as soft, sealed capsules made of gelatin and a plasticizer,
such as glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as, e.g., lactose,
binders such as, e.g., starches, and/or lubricants such as, e.g.,
talc or magnesium stearate and, optionally, stabilizers. In soft
capsules, the active compounds can be dissolved or suspended in
suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers can be added. All
compositions for oral administration should be in dosages suitable
for such administration.
[0166] For buccal administration, the estrogen and progestin
compositions can take the form of tablets or lozenges formulated in
conventional manner.
[0167] For administration by inhalation, the estrogen and/or
progestin for use according to the present invention are
conveniently delivered in the form of an aerosol spray presentation
from pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol the dosage unit can be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of, e.g., gelatin for use in an inhaler or insufflator
can be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0168] The estrogen and/or progestin can be formulated for
parenteral administration by injection, e.g., by bolus injection or
continuous infusion. The compounds can be administered by
continuous infusion subcutaneously over a period of about 15
minutes to about 24 hours. Compositions for injection can be
presented in unit dosage form, e.g., in ampoules or in multi-dose
containers, with an added preservative. The compositions can take
such forms as suspensions, solutions or emulsions in oily or
aqueous vehicles, and can contain formulatory agents such as
suspending, stabilizing and/or dispersing agents.
[0169] The estrogen and/or progestin can also be formulated in
rectal compositions such as suppositories or retention enemas,
e.g., containing conventional suppository bases such as cocoa
butter or other glycerides.
[0170] In addition to the compositions described previously, the
estrogen and/or progestin can also be formulated as a depot
preparation. Such long acting compositions can be administered by
implantation (e.g., subcutaneously or intramuscularly) or by
intramuscular injection. Depot injections can be administered at
about 1 to about 6 months or longer intervals. Thus, for example,
the estrogen and/or progestin can be formulated with suitable
polymeric or hydrophobic materials (e.g., as an emulsion in an
acceptable oil) or ion exchange resins, or as sparingly soluble
derivatives, for example, as a sparingly soluble salt.
[0171] For transdermal administration, the estrogen and/or
progestin can be applied by any transdermal, therapeutic system
that is consequently supplied to the organism, such as, for
example, as a transdermal patch, transdermal cream or plaster. For
example, the estrogen and/or progestin can be formulated as a
transdermal patch. The preparation and use of transdermal patches
are well known to those of skill in the art and are available in
different designs, including matrix-type or reservoir-type designs.
In addition to the estrogen and/or progestin, transdermal patches
can contain additional components such as penetration-enhancing
agents and/or additional excipients that are conventionally
employed, such as, e.g., carriers, gelling agents, suspending
agents, dispersing agents, preservatives, stabilizers, wetting
agents, emulsifying agents, and the like.
[0172] For vaginal administration, the estrogen and/or progestin
can be formulated as vaginal gels, creams, tampons, suppositories,
vaginal rings, intrauterine devices and the like. The preparation
of each of these formulations is well known to those of skill in
the art.
[0173] The estrogen and/or progestin can also be administered with
other active ingredients. The hormone-free period or the unopposed
estrogen interval can also include administration of other active
ingredients. For example, as described above, estrogen and/or
progestin can be administered in combination with an
antidepressant. Estrogen and/or progestin can also be administered
with vitamin D and/or calcium in the ascending-dose extended cycle
regimens as a method of maintaining or preventing loss of bone
density. Alternatively, vitamin D and/or calcium can be
administered in the ascending-dose extended cycle regimens during
the unopposed estrogen interval following administration of
estrogen and/or progestin. The form of vitamin D and of calcium
used in the present invention would be well known to those of skill
in the art, as would the amount. For example, calcium can be
administered in the form of calcium carbonate, at a dosage level of
e.g., 500 mg.
[0174] In some aspects of the invention, the estrogen and/or
progestin are in a oral, transdermal, intravaginal, implantable
pellet, or injectable liquid dosage form. For example, the estrogen
and/or progestin can be in an oral dosage form, a transdermal
dosage form, or an intravaginal dosage form.
[0175] In some aspects of the invention, the estrogen and progestin
can be combined in one dosage form. In other aspects of the
invention, the estrogen and progestin can be provided in different
or separate dosage forms. Similarly, other active ingredients can
be provided in the same, different, or separate dosage forms.
[0176] In some aspects of the invention, each phase of the regimen
of the invention can be administered in a separate, single dosage
form. In other aspects of the invention, each phase of the regimen
of the invention can be administered in one or more separate dosage
forms. For example, each phase can be administered using a separate
ring or transdermal device (such as a patch). As another example,
each phase can be administered using one or more rings or
transdermal devices.
[0177] The present invention also provides a combination of two or
more modes of administration with each regimen. For example, the
estrogen can be provided by transdermal administration and the
progestin can be provided by vaginal administration. As another
example, the estrogen can be provided by transdermal
administration, the progestin can be provided by transdermal
administration, and an SSRI can be provided by oral
administration.
Kits and Patient Education
[0178] The dosages or compositions for the ascending-dose extended
cycle regimens of the invention can be provided in the form of a
kit or package, with the dosages arranged for proper sequential
administration. For example, in the oral form of the composition,
the present invention provides a pharmaceutical package which
contains combination-type contraceptives in multiple dosage units
in a synchronized, fixed sequence, wherein the sequence or
arrangement of the dosage units corresponds to the stages of daily
administration.
[0179] Thus, for example, the pharmaceutical compositions useful in
the invention can be provided in kit form containing greater than
30 or 31 tablets intended for ingestion on successive days. In some
embodiments, the kit further contains, e.g., 2 to 10 tablets,
intended for ingestion on successive days following the ingestion
of the greater than 30 or 31 tablets. Administration is daily for a
period of greater than 30 or 31 consecutive days using tablets
containing both the estrogen and the progestin, and, in some
embodiments, is followed by administration that is daily for, e.g.,
2 to 10 consecutive days using either placebo tablets or tablets
containing estrogen. For example, administration can be for 40-190
consecutive days, using tablets containing both estrogen and the
progestin, followed by administration for, e.g., at least 2-10 days
with estrogen, using tablets containing estrogen. As another
example, administration can be for 75-95 days, using tablets
containing both an estrogen and a progestin, followed by
administration for, e.g., at least 2-10 days with estrogen, using
tablets containing estrogen. As yet another example, administration
can be for 168-186 days, using tablets containing both an estrogen
and a progestin, followed by administration for, e.g., at least
2-10 days with estrogen, using tablets containing estrogen.
[0180] Some aspects of the invention provide a pharmaceutical kit
comprising a first oral dosage capable of providing a daily dosage
of estrogen and a daily dosage of progestin; a second oral dosage
capable of providing a daily dosage of estrogen that is equal to or
higher than that of the first oral dosage and capable of providing
a total daily dosage of estrogen and progestin that is higher than
that of the first oral dosage; and a third oral dosage capable of
providing a daily dosage of estrogen that is equal to or higher
than that of the second oral dosage and capable of providing a
total daily dosage of estrogen and progestin that is higher than
that of the second oral dosage; wherein the oral dosages are
capable of providing estrogen and progestin for a period of greater
than 30 or 31 consecutive days.
[0181] Other aspects of the invention provide a pharmaceutical kit
comprising a first oral dosage capable of providing a daily dosage
of estrogen and a daily dosage of progestin; a second oral dosage
capable of providing a total daily dosage of estrogen and progestin
that is higher than that of the first oral dosage and capable of
providing a daily dosage of progestin that is less than twice that
of the first oral dosage; wherein the oral dosages are capable of
providing estrogen and progestin for a period of greater than 42
consecutive days. In some aspects of the invention, the second oral
dosage is capable of providing a daily dosage of estrogen that is
equal to or higher than that of the first oral dosage. In some
aspects of the invention, the pharmaceutical kit includes greater
than 30 or 31 oral daily dosages.
[0182] In some embodiments, a pharmaceutical kit of the present
invention comprises 14 to 28 first oral dosages, 14 to 28 second
oral dosages, and 35 to 53 third oral dosages. For example, a
pharmaceutical kit of the present invention can contain 21 first
oral dosages, 21 second oral dosages, and 42 third oral
dosages.
[0183] In some embodiments, a pharmaceutical kit of the present
invention comprises 14 to 28 first oral dosages, 35 to 49 second
oral dosages, and 14 to 32 third oral dosages. For example, a
pharmaceutical kit of the present invention can contain 21 first
oral dosages, 42 second oral dosages, and 21 third oral
dosages.
[0184] In some embodiment, a pharmaceutical kit of the present
invention comprises 35 to 49 first oral dosages, 14 to 28 second
oral dosages, and 14 to 32 third oral dosages. For example, a
pharmaceutical kit of the present invention can contain 42 first
oral dosages, 21 second oral dosages, and 21 third oral
dosages.
[0185] In some embodiments, the first oral dosage is capable of
providing 20 .mu.g of ethinyl estradiol and 150 .mu.g of
levonorgestrel, the second oral dosage is capable of providing 25
.mu.g of ethinyl estradiol and 150 .mu.g of levonorgestrel, and the
third oral dosage is capable of providing 30 .mu.g of ethinyl
estradiol and 150 .mu.g of levonorgestrel.
[0186] The pharmaceutical kits of the present invention can further
contain a fourth oral dosage capable of providing estrogen. In some
embodiments, the fourth oral dosage comprises a daily equivalent of
10 .mu.g of ethinyl estradiol. In some embodiments, a
pharmaceutical kit according to the present invention comprises 2
to 10 fourth oral dosages. For example, a pharmaceutical kit of the
present invention can contain 3 or 7 fourth oral dosages.
[0187] Some aspects of the invention provide a pharmaceutical kit
comprising a first vaginal ring capable of providing a daily dosage
of estrogen and a daily dosage of progestin; a second vaginal ring
capable of providing a daily dosage of estrogen that is equal to or
higher than that of the first vaginal ring and capable of providing
a total daily dosage of estrogen and progestin that is higher than
that of the first vaginal ring; and a third vaginal ring capable of
providing a daily dosage of estrogen that is equal to or higher
than that of the second vaginal ring and capable of providing a
total daily dosage of estrogen and progestin that is higher than
that of the second vaginal ring; wherein the vaginal rings are
capable of providing estrogen and progestin for a period of greater
than 30 or 31 consecutive days.
[0188] Other aspects of the invention provide a pharmaceutical kit
comprising a first vaginal ring capable of providing a daily dosage
of estrogen and a daily dosage of progestin; a second vaginal ring
capable of providing a total daily dosage of estrogen and progestin
that is higher than that of the first vaginal ring and capable of
providing a daily dosage of progestin that is less than twice that
of the first vaginal ring; wherein the vaginal rings are capable of
providing estrogen and progestin for a period of greater than 30 or
31 consecutive days. In some aspects of the invention, the second
vaginal ring is capable of providing a daily dosage of estrogen
that is equal to or higher than that of the first vaginal ring.
[0189] Some aspects of the invention provide a pharmaceutical kit
comprising a first transdermal device capable of providing a daily
dosage of estrogen and a daily dosage of progestin; a second
transdermal device capable of providing a daily dosage of estrogen
that is equal to or higher than that of the first transdermal
device and capable of providing a total daily dosage of estrogen
and progestin that is higher than that of the first transdermal
device; and a third transdermal device capable of providing a daily
dosage of estrogen that is equal to or higher than that of the
second transdermal device and capable of providing a total daily
dosage of estrogen and progestin that is higher than that of the
second transdermal device; wherein the transdermal devices are
capable of providing estrogen and progestin for a period of greater
than 30 or 31 consecutive days.
[0190] Other aspects of the invention provide a pharmaceutical kit
comprising a first transdermal device capable of providing a daily
dosage of estrogen and a daily dosage of progestin; a second
transdermal device capable of providing a total daily dosage of
estrogen and progestin that is higher than that of the first
transdermal device and capable of providing a daily dosage of
progestin that is less than twice that of the first transdermal
device; wherein the transdermal devices are capable of providing
estrogen and progestin for a period of greater than 30 or 31
consecutive days. In some aspects of the invention, the second
transdermal device is capable of providing a daily dosage of
estrogen that is equal to or higher than that of the first
transdermal device.
[0191] The pharmaceutical kits of the invention can further include
instructions for proper sequential administration in accordance
with the regimens of the present invention.
[0192] The present invention is also directed to a method of
delivering a pharmaceutical composition for an ascending-dose
extended cycle regimen of the present invention to a patient in
need thereof, the method comprising (a) registering in a computer
readable medium the identity of a physician permitted to prescribe
a pharmaceutical composition for an ascending-dose extended cycle
regimen; (b) providing the patient with counseling information
concerning the risks attendant to the pharmaceutical composition;
(c) obtaining informed consent from the patient to receive the
pharmaceutical composition despite the attendant risks; (d)
registering the patient in a computer readable medium after
obtaining their informed consent; and (e) permitting the patient
access to the pharmaceutical composition.
[0193] The drug delivery methods of the present invention involve,
inter alia, registering in a computer readable storage medium
physicians who are qualified to prescribe the ascending-dose
extended cycle regimen of the present invention. Once registered in
the computer readable storage medium, the physician can be eligible
to prescribe the pharmaceutical composition to a patient in need
thereof. Generally speaking, in order to become registered in the
computer readable storage medium, the physician may be required to
comply with various aspects of, for example, providing patient
education and counseling. The registration of the physician in the
computer readable storage medium can be achieved by providing the
physician, for example, by mail, facsimile transmission, or on-line
transmission, with a registration card or form, preferably together
with educational materials concerning the pharmaceutical
composition of the present invention. The physician can complete
the registration card or form by providing information requested
therein, and the registration card or form can be returned to the
manufacturer or distributor of the pharmaceutical composition of
the present invention, or other authorized recipient of the
registration materials, for example, by mail, facsimile
transmission or on-line transmission. The physician's information
in the registration card or form is then entered into the computer
readable storage medium. Suitable computer readable storage media
which can be employed for registration of the physicians (as well
as patients, as discussed below) will be apparent to one of
ordinary skill in the art, once in possession of the teaching of
the present application.
[0194] In the course of examination of a patient, the physician may
determine that the patient's condition can be improved by the
administration of the pharmaceutical composition of the present
invention. Prior to prescribing the pharmaceutical composition of
the present invention, the physician can counsel the patient, for
example, on the various risks and benefits associated with the
pharmaceutical composition of the present invention. The patient
can be provided full disclosure of all the known and suspected
risks associated with the pharmaceutical composition of the present
invention. Such counseling can be provided verbally, as well as in
written form. In some embodiments, the physician can provide the
patient with literature materials on the pharmaceutical composition
of the present invention, such as product information, educational
materials, and the like.
[0195] In addition to receiving counseling on the risks attendant
to the pharmaceutical composition of the present invention, the
methods of the invention further require the patient to fill out an
informed consent form which is signed by the patient. Upon the
completion of the informed consent form, the patient can be
registered in a computer readable storage medium. The computer
readable storage medium in which the patient is registered can be
the same as, or different from, the computer readable storage
medium in which the physician is registered.
[0196] The registration into one or more computer readable storage
media of the physician and patient, according to the methods
describe herein, provides a means to monitor and authorize access
to the pharmaceutical composition of the present invention. Thus,
the computer readable storage medium can serve to deny access to
patients who fail to abide by the methods of the present invention.
In some embodiments, access to the pharmaceutical composition of
the present invention is in the form of a prescription, wherein the
prescribing physician is registered in a computer readable storage
medium, has provided counseling to the patient concerning the
attendant risks of the pharmaceutical composition of the present
invention, and has obtained informed consent from the patient,
prior to prescribing the pharmaceutical composition of the present
invention to the patient in need thereof.
[0197] All of the various aspects, embodiments and options
described herein can be combined in any and all variations. The
following examples are illustrative, but not limiting, of the
method and compositions of the present invention. Other suitable
modifications and adaptations of the variety of conditions and
parameters normally encountered and obvious to those skilled in the
art are within the spirit and scope of the invention. Thus, the
breadth and scope of the present invention should not be limited by
any of the above-described exemplary embodiments, but should be
defined only in accordance with the following claims and their
equivalents.
EXAMPLES
Example 1
[0198] Tables 2-6 below show examples of ascending-dose extended
cycle regimens for 2-month, 3-month, 4-month, 5-month, and 6-month
cycles, respectively. All regimens below comprise three phases,
wherein an equivalent of 20 .mu.g of ethinyl estradiol is
administered in the first phase, 25 .mu.g of ethinyl estradiol is
administered in the second phase, and 30 .mu.g of ethinyl estradiol
is administered in the third phase. For all regimens below, an
equivalent of 150 .mu.g of levonorgestrel is administered in all
three phases. For each regimen below, two possibilities are
provided for phase 3, one corresponding to an allowance of 7 days
of placebo following the administration of the estrogen and
progestin, and the other corresponding to an allowance of 3 days of
placebo following the administration of the estrogen and progestin.
TABLE-US-00002 TABLE 2 Two-Month Ascending-Dose Extended Cycle
Regimen No. of days in Total estrogen Total progestin Phases each
phase dose (.mu.g) dose (.mu.g) 1 14 280 2 21 525 3 (with 7 days
placebo 14 420 or 3 days placebo) 18 540 Total 49 (active) 1225
7350 (with 7 days placebo or 3 days placebo) 53 (active) 1345 7950
Comparable Dose (2 42 active 1260 6300 cycles of 28-day 14 placebo
monophasic 30 .mu.g ethinyl estradiol oral contraceptive)
[0199] TABLE-US-00003 TABLE 3 Three-Month Ascending-Dose Extended
Cycle Regimen No. of days in Total estrogen Total progestin Phases
each phase dose (.mu.g) dose (.mu.g) 1 21 420 2 21 525 3 (with 7
days placebo 42 1260 or 3 days placebo) 46 1380 Total 84 (active)
2205 12600 (with 7 days placebo or 3 days placebo) 88 (active) 2325
13200 Comparable Dose 84 2520 12600 (1 cycle of Seasonale .RTM.; 91
days)
[0200] TABLE-US-00004 TABLE 4 Four-Month Ascending-Dose Extended
Cycle Regimen No. of days in Total estrogen Total progestin Phases
each phase dose (.mu.g) dose (.mu.g) 1 21 420 2 42 1050 3 (with 7
days placebo 42 1260 or 3 days placebo) 46 1380 Total 105 (active)
2730 15750 (with 7 days placebo or 3 days placebo) 109 (active)
2850 16350 Comparable Dose (4 112 (84 active 2520 12600 cycles of
28-day .sup. days) monophasic 30 .mu.g ethinyl estradiol oral
contraceptive)
[0201] TABLE-US-00005 TABLE 5 Five-Month Ascending-Dose Extended
Cycle Regimen No. of days in Total estrogen Total progestin Phases
each phase dose (.mu.g) dose (.mu.g) 1 42 840 2 49 1225 3 (with 7
days placebo 42 1260 or 3 days placebo) 46 1380 Total 133 (active)
3325 19950 (with 7 days placebo or 3 days placebo) 137 (active)
3445 20550 Comparable Dose (5 140 (105 3150 15750 cycles of 28-day
.sup. active monophasic 30 .mu.g .sup. days) ethinyl estradiol oral
contraceptive)
[0202] TABLE-US-00006 TABLE 6 Six-Month Ascending-Dose Extended
Cycle Regimen No. of days in Total estrogen Total progestin Phases
each phase dose (.mu.g) dose (.mu.g) 1 42 840 2 63 1575 3 (with 7
days placebo 70 2100 or 3 days placebo) 74 2220 Total 175 (active)
4515 26250 (with 7 days placebo or 3 days placebo) 179 (active)
4635 26850 Comparable Dose 168 (active) 5040 25200 (2 cycle of
Seasonale .RTM.; 91 days)
[0203] TABLE-US-00007 TABLE 7 One-Year Ascending-Dose Extended
Cycle Regimen No. of days in Total estrogen Total progestin Phases
each phase dose (.mu.g) dose (.mu.g) 1 56 1120 2 175 4375 3 (with 7
days placebo 126 3780 or 3 days placebo) 130 3900 Total 357
(active) 9275 53550 (with 7 days placebo or 3 days placebo) 361
(active) 9395 54150
Example 2
[0204] A clinical study is contemplated, as follows, using
ascending-dose extended cycle regimens in accordance with the
present invention.
[0205] The primary objective of this study is to evaluate and
compare bleeding patterns and hormone-related symptoms in women
receiving one of the following three different ascending dose
extended cycle (91-day) oral contraceptive regimens, each having
combination active tablets containing ethinyl estradiol (EE) and
levonorgestrel (LNG), followed by EE tablets during the seven-day
interval between each 84-day cycle of combination therapy:
[0206] Regimen I: Subjects will utilize a regimen of 42 days
combination active tablets (20 .mu.g EE/150 .mu.g LNG) followed by
21 days combination active tablets (25 .mu.g EE/150 .mu.g LNG)
followed by 21 days combination active tablets (30 .mu.g EE/150
.mu.g LNG) followed by 7 days of 10 .mu.g EE tablets for two
consecutive 91-day cycles.
[0207] Regimen II: Subjects will utilize a regimen of 21 days
combination active tablets (20 .mu.g EE/150 .mu.g LNG) followed by
42 days combination active tablets (25 .mu.g EE/150 .mu.g LNG)
followed by 21 days combination active tablets (30 .mu.g EE/150
.mu.g LNG) followed by 7 days of 10 .mu.g EE tablets for two
consecutive 91-day cycles.
[0208] Regimen III: Subjects will utilize a regimen of 21 days
combination active tablets (20 .mu.g EE/150 .mu.g LNG) followed by
21 days combination active tablets (25 .mu.g EE/150 .mu.g LNG)
followed by 42 days combination active tablets (30 .mu.g EE/150
.mu.g LNG) followed by 7 days of 10 .mu.g EE tablets for two
consecutive 91-day cycles.
[0209] The duration of the study is approximately 9 months,
depending on where the subject is in her cycle at the time of
screening. A conventional 28-day cycle contraceptive regimen, such
as Portia.RTM. (Barr Laboratories, Inc., Woodcliff Lake, N.J.) can
be used prior to administering the ascending-dose extended cycle
regimens of the present invention.
[0210] The ascending-dose extended cycle regimens will be
administered for two consecutive 91-day extended cycles (26 weeks).
There will be 9 study visits, which will include a screening visit,
a run-in visit, a randomization visit, five study visits occurring
every 4-6 weeks during the 26 week treatment period (weeks 4, 10,
16, 22, and 26), and a final study visit occurring 14-21 days after
completion of study medication
[0211] Application of the compounds, compositions and methods of
the present invention for the medical or pharmaceutical uses
described can be accomplished by any clinical, medical, and
pharmaceutical methods and techniques as are presently or
prospectively known to those skilled in the art. It will therefore
be appreciated that the various embodiments which have been
described above are intended to illustrate the invention and
various changes and modifications can be made in the invention
method without departing from the spirit or scope thereof.
[0212] Having now fully described this invention, it will be
understood to those of ordinary skill in the art that the same can
be performed within a wide and equivalent range of conditions,
compositions, and other parameters without affecting the scope of
the invention or any embodiments thereof. All patents, patent
applications, and publications cited herein are fully incorporated
by reference herein in their entirety.
* * * * *